[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 96 of about 96
1. Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan SF, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, Jarbadan NR, Broeg K, Zhang R, Liao J, Sayers TJ, Kester M, Loughran TP Jr: Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood; 2010 Nov 18;116(20):4192-201
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.
  • The natural killer (NK) type of aggressive large granular lymphocytic (LGL) leukemia is a fatal illness that pursues a rapid clinical course.
  • There are no effective therapies for this illness, and pathogenetic mechanisms remain undefined.
  • Here we report that the survivin was highly expressed in both aggressive and chronic leukemic NK cells but not in normal NK cells.
  • In vitro treatment of human and rat NK-LGL leukemia cells with cell-permeable, short-chain C₆-ceramide (C₆) in nanoliposomal formulation led to caspase-dependent apoptosis and diminished survivin protein expression, in a time- and dose-dependent manner.
  • Importantly, systemic intravenous delivery of nanoliposomal ceramide induced complete remission in the syngeneic Fischer F344 rat model of aggressive NK-LGL leukemia.
  • Therapeutic efficacy was associated with decreased expression of survivin in vivo.
  • These data suggest that in vivo targeting of survivin through delivery of nanoliposomal C₆-ceramide may be a promising therapeutic approach for a fatal leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Cell Physiol. 2001 Jun;280(6):C1403-11 [11350735.001]
  • [Cites] Mol Biol Cell. 2009 Apr;20(7):2041-8 [19211844.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3286-92 [11723139.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cell Signal. 2002 Sep;14(9):779-85 [12034359.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):401-10 [12042762.001]
  • [Cites] Adv Enzyme Regul. 2002;42:113-29 [12123710.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):619-31 [12145814.001]
  • [Cites] FEBS Lett. 2002 Oct 23;530(1-3):9-16 [12387858.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23130-40 [12660240.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2683-92 [12855648.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):221-32 [12876671.001]
  • [Cites] Nat Cell Biol. 1999 Dec;1(8):461-6 [10587640.001]
  • [Cites] Circ Res. 2000 Aug 18;87(4):282-8 [10948061.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):635-40 [11149963.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41482-90 [12902349.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Nov;307(2):468-75 [12975495.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8581-9 [14634620.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3663-9 [14666662.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):337-46 [14729643.001]
  • [Cites] J Clin Invest. 2004 Oct;114(8):1117-27 [15489959.001]
  • [Cites] J Immunol. 1984 Jan;132(1):534-40 [6197459.001]
  • [Cites] Am J Pathol. 1985 Jun;119(3):517-9 [3874555.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Exp Hematol. 1996 Feb;24(3):406-15 [8599969.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):123-6 [9136951.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4771-7 [9845544.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9220-9 [15516985.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3465-74 [15867249.001]
  • [Cites] Glia. 2005 Dec;52(4):309-24 [16078232.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Dec 15;172(12):1487-90 [16151040.001]
  • [Cites] Oncologist. 2006 Mar;11(3):263-73 [16549811.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):1129-34 [17373752.001]
  • [Cites] Hum Pathol. 2007 May;38(5):710-7 [17391730.001]
  • [Cites] Apoptosis. 2007 May;12(5):923-39 [17294080.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):5999-6002 [17616652.001]
  • [Cites] Toxicol Sci. 2007 Sep;99(1):3-19 [17522071.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7569-75 [17546047.001]
  • [Cites] Biochem Pharmacol. 2008 May 15;75(10):1946-58 [18377872.001]
  • [Cites] BMC Cancer. 2008;8:129 [18454859.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3571-81 [18519791.001]
  • [Cites] Drug Metab Dispos. 2008 Aug;36(8):1709-15 [18490436.001]
  • [Cites] Nano Lett. 2008 Aug;8(8):2559-63 [18611058.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7638-49 [18794153.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3247-57 [11714700.001]
  • (PMID = 20671121.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA133525; United States / NCI NIH HHS / CA / R01 CA098472; United States / NCI NIH HHS / CA / CA133525; United States / NCI NIH HHS / CA / CA098472; United States / NCI NIH HHS / CA / N01CO12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Birc5 protein, rat; 0 / Ceramides; 0 / Liposomes; 0 / Microtubule-Associated Proteins; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2993625
  •  go-up   go-down


2. Alekshun TJ, Sokol L: Diseases of large granular lymphocytes. Cancer Control; 2007 Apr;14(2):141-50
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diseases of large granular lymphocytes.
  • BACKGROUND: Clonal diseases of large granular lymphocytes (LGLs) are rare lymphoproliferative malignancies that arise from either mature T-cell (CD3+) or natural killer (NK)-cell (CD3-) lineages.
  • They manifest a distinct biologic behavior that ranges from indolent to very aggressive.
  • METHODS: We discuss four distinct diseases involving LGLs: indolent T-cell LGL leukemia, aggressive T-cell LGL leukemia, chronic NK-cell leukemia, and aggressive NK-cell leukemia.
  • Furthermore, we present an up-to-date systematic review of therapies for each entity.
  • RESULTS: Sustained LGLs, characteristic immunophenotype, clonal origin of leukemic cells, and clinical presentation are the most important features that distinguish indolent from aggressive subtypes of LGL leukemia and guide the selection of therapy.
  • Patients with symptomatic indolent T-cell or NK-cell LGL leukemia are usually treated with immunosuppressive therapies in contrast to aggressive T-cell and NK-cell LGL leukemia, which require intensive chemotherapy induction regimens.
  • Novel targeted therapies using monoclonal antibodies against receptors, including CD2, CD52, the beta subunit of the interleukin-2 receptor, and small molecules such as tipifarnib, are undergoing evaluation in clinical trials.
  • CONCLUSIONS: Future scientific advances focusing on the delineation of molecular pathogenic mechanisms and the development of new targeted therapies for each distinct LGL leukemia entity should lead to improved outcomes of patients with these disorders.
  • [MeSH-major] Antigens, CD3. Killer Cells, Natural / pathology. Leukemia, Lymphoid / pathology. Leukemia, T-Cell / pathology. Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387299.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3
  • [Number-of-references] 71
  •  go-up   go-down


3. Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP Jr, Wei S: Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood; 2008 Dec 1;112(12):4694-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling.
  • Large granular lymphocyte (LGL) leukemia is commonly associated with poor hematopoiesis.
  • The first case of pulmonary artery hypertension (PAH) was observed in a 57-year-old woman with natural killer (NK)-LGL leukemia and transfusion-dependent anemia.
  • Using a genetic approach, we demonstrated that killing of pulmonary endothelial cells by patient NK cells was mediated by dysregulated balance in activating and inhibitory NK-receptor signaling.
  • Elevated pulmonary artery pressure and erythroid differentiation improved after disrupting the NK-receptor signaling pathway with 4 courses of a farnesyltransferase inhibitor, tipifarnib.
  • Coincidental association between PAH and LGL leukemia suggest a causal relationship between the expanded lymphocyte population and these clinical manifestations.

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1997 Jan 9;336(2):111-7 [8988890.001]
  • [Cites] Immunol Rev. 1997 Feb;155:145-54 [9059890.001]
  • [Cites] Chest. 1997 Aug;112(2):551-3 [9266900.001]
  • [Cites] Immunity. 1998 Jun;8(6):693-701 [9655483.001]
  • [Cites] J Biol Chem. 1998 Dec 18;273(51):34115-9 [9852069.001]
  • [Cites] Science. 1999 Jul 30;285(5428):727-9 [10426993.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9220-9 [15516985.001]
  • [Cites] Curr Opin Immunol. 2005 Feb;17(1):29-35 [15653307.001]
  • [Cites] Exp Hematol. 2005 Nov;33(11):1357-62 [16263420.001]
  • [Cites] Br J Haematol. 2007 Jan;136(2):237-48 [17156396.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1627-36 [10587353.001]
  • [Cites] Br J Haematol. 2000 Mar;108(4):717-23 [10792274.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):1059-68 [11015446.001]
  • [Cites] J Immunol. 2000 Oct 1;165(7):3811-9 [11034387.001]
  • [Cites] Immunol Today. 2000 Dec;21(12):611-4 [11114420.001]
  • [Cites] Annu Rev Immunol. 2001;19:197-223 [11244035.001]
  • [Cites] J Exp Med. 2001 Aug 20;194(4):455-69 [11514602.001]
  • [Cites] J Clin Invest. 2002 Jan;109(2):161-8 [11805126.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1797-805 [12750175.001]
  • [Cites] Blood. 2004 May 1;103(9):3431-9 [14726391.001]
  • [Cites] Ann Intern Med. 1985 Feb;102(2):169-75 [3966754.001]
  • [Cites] Ann Intern Med. 1987 Aug;107(2):216-23 [3605900.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12433-8 [8901599.001]
  • (PMID = 18791165.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098472; United States / NCRR NIH HHS / RR / U54 RR019397; United States / NIAID NIH HHS / AI / AI056213; United States / NCI NIH HHS / CA / CA94872; United States / NCRR NIH HHS / RR / U54RR019397-05; United States / NCI NIH HHS / CA / CA11211201; United States / NIAID NIH HHS / AI / R01 AI056213
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Quinolones; 0 / Receptors, Natural Killer Cell; 192185-72-1 / tipifarnib; EC 2.5.1.29 / Farnesyltranstransferase
  • [Other-IDs] NLM/ PMC2597136
  •  go-up   go-down


Advertisement
4. Saitoh T, Karasawa M, Sakuraya M, Norio N, Junko T, Shirakawa K, Matsushima T, Tsukamoto N, Nojima Y, Murakami H: Improvement of extrathymic T cell type of large granular lymphocyte (LGL) leukemia by cyclosporin A: the serum level of Fas ligand is a marker of LGL leukemia activity. Eur J Haematol; 2000 Oct;65(4):272-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of extrathymic T cell type of large granular lymphocyte (LGL) leukemia by cyclosporin A: the serum level of Fas ligand is a marker of LGL leukemia activity.
  • We report a case of gammadelta T-cell-type large granular lymphocyte (LGL) leukemia (CD3 +,CD8 +, CD57 +,TCR gammadelta+), which was accompanied by pure red cell aplasia, neutropenia and thrombocytosis.
  • Southern blotting analysis of the T-cell receptor beta gene showed the germline configuration, but clonal TCR J gamma rearrangements were identified.
  • These granular lymphocytes demonstrated non-major histocompatibility complex-restricted cytotoxicitity.
  • After treatment with cyclosporin A, anemia and thrombocytosis were improved, and LGL and the elevated sFasL concentration decreased.
  • These observations suggested that FasL may have played a role in the establishment of the clinical symptoms of this patient and could be useful as an indicator of disease activity.
  • [MeSH-major] Cyclosporine / administration & dosage. Leukemia, Lymphoid / drug therapy. Leukemia, T-Cell / drug therapy
  • [MeSH-minor] Antigens, CD3 / blood. Antigens, CD95 / blood. Humans. Immunophenotyping. Male. Middle Aged. Receptors, Antigen, T-Cell, gamma-delta / blood. Red-Cell Aplasia, Pure / drug therapy. Red-Cell Aplasia, Pure / etiology. Thrombocytosis / drug therapy. Thrombocytosis / etiology. Treatment Outcome


5. Burks EJ, Loughran TP Jr: Perspectives in the treatment of LGL leukemia. Leuk Res; 2005 Feb;29(2):123-5
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspectives in the treatment of LGL leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Lymphoid / drug therapy
  • [MeSH-minor] Clinical Trials as Topic / statistics & numerical data. Humans. Leukemia, T-Cell / classification. Leukemia, T-Cell / drug therapy. Leukemia, T-Cell / etiology. Leukocyte Count

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Res. 2005 Feb;29(2):225-8 [15607372.001]
  • (PMID = 15607357.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comment; Editorial; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down


6. Sretenovic A, Antic D, Jankovic S, Gotic M, Perunicic-Jovanovic M, Jakovic L, Mihaljevic B: T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience. Med Oncol; 2010 Jun;27(2):286-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience.
  • BACKGROUND: T-cell large granular lymphocytic (T-LGL) leukemia is a rare lymphoproliferative disease which usually affects elderly people.
  • The clinical course of T-LGL leukemia is generally indolent, with lymphocytosis and splenomegaly in 20-50% patients, hepatomegaly in 5-20% of patients, and less commonly, lymphadenopathy.
  • T-LGL leukemia is associated with immunological abnormalities: rheumatoid factor with or without rheumatoid arthritis (RA), Coombs positive hemolytic anemia, idiopathic thrombocytopenic purpura (ITP), pure red cell aplasia (PRCA), positive anti-nuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies (ANCA), hypogammaglobulinemia, and polyclonal hypergammaglobulinemia.
  • Aim To compare clinical and laboratory features of T-LGL leukemia patients and their responses to different chemotherapy regimens.
  • METHODS: Six patients (3 males and 3 females) with T-LGL leukemia were analyzed.
  • The diagnosis was based on accepted morphologic criteria, immunophenotype, and polymerase chain reaction (PCR) detection of T-cell receptor (TCR) gene rearrangements.
  • RESULTS: All patients exhibited lymphocytosis, mainly with unusual morphologies, splenomegaly, and elevated serum lactate dehydrogenase (LDH).
  • Three patients were treated with a Fludarabine-Cyclophosphamide (FC) combination as initial therapy while three patients received CHOP.
  • Two patients received more than one treatment regimen.
  • One patient died due to T-LGL leukemia in first year after diagnosis, one patient died 4 years after diagnosis, two patients interrupted their treatment, and two patients are still alive.
  • CONCLUSIONS: Further prospective studies are needed for establishing a gold standard therapy for T-LGL leukemia.
  • [MeSH-major] Leukemia, Large Granular Lymphocytic / blood. Leukemia, Large Granular Lymphocytic / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / therapeutic use. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2003 Jan;22(1):33-9 [12469182.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1116-9 [1355373.001]
  • [Cites] Ann Intern Med. 1998 Jul 1;129(1):49-58 [9653000.001]
  • [Cites] Blood. 1990 Feb 1;75(3):704-8 [2297572.001]
  • [Cites] Leuk Res. 2007 Jul;31(7):939-45 [17045649.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):570-8 [16795070.001]
  • [Cites] J Clin Pathol. 1998 Sep;51(9):672-5 [9930071.001]
  • [Cites] Oncologist. 2006 Mar;11(3):263-73 [16549811.001]
  • [Cites] Leuk Lymphoma. 2005 May;46(5):723-7 [16019510.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):278-81 [14531909.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):123-6 [9136951.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2225-6 [17525720.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):699-701 [12588360.001]
  • [Cites] Orv Hetil. 1997 Aug 17;138(33):2075-80 [9304100.001]
  • [Cites] Br J Haematol. 1998 May;101(2):318-24 [9609528.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):449-53 [14617004.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:259-81 [11722988.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1969-71 [14976065.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2164-70 [7919331.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2427-38 [15621755.001]
  • (PMID = 19306076.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


7. Sokol L, Loughran TP Jr: Large granular lymphocyte leukemia. Oncologist; 2006 Mar;11(3):263-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocyte leukemia.
  • Clonal disorders of large granular lymphocytes (LGLs) represent a spectrum of biologically distinct lymphoproliferative diseases originating either from mature T cells (CD3+) or natural killer (NK) cells (CD3-).
  • Both subtypes, T-cell and NK-cell LGL leukemia, can manifest as indolent or aggressive disorders.
  • The majority of patients with T-cell LGL leukemia have a clinically indolent course with a median survival time >10 years.
  • Immunosuppressive therapy with low-dose methotrexate, cyclophosphamide, or cyclosporine A can control symptoms and cytopenias in more than 50% of patients, but this approach is not curative.
  • Several cases of an aggressive variant (CD3+ CD56+) of T-cell LGL leukemia with a poor prognosis have also been reported.
  • Aggressive NK-cell LGL leukemia is usually a rapidly progressive disorder associated with Epstein-Barr virus (EBV), with a higher prevalence in Asia and South America.
  • This disease is usually refractory to conventional chemotherapy, with a median survival time of 2 months.
  • Chronic NK-cell leukemia/lymphocytosis is a rare EBV-negative disorder with an indolent clinical course.
  • The malignant origin of this subtype is uncertain because clonality is difficult to determine in LGLs of NK-cell origin.
  • [MeSH-major] Leukemia, T-Cell / diagnosis. Leukemia, T-Cell / therapy
  • [MeSH-minor] Algorithms. Autoimmune Diseases / etiology. Cytogenetic Analysis. Diagnosis, Differential. Hematologic Diseases / etiology. Humans. Phenotype

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549811.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


8. Osuji N, Matutes E, Tjonnfjord G, Grech H, Del Giudice I, Wotherspoon A, Swansbury JG, Catovsky D: T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature. Cancer; 2006 Aug 1;107(3):570-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature.
  • BACKGROUND: To the authors' knowledge, there is no standard treatment for patients with T-cell large granular lymphocyte (LGL) leukemia.
  • METHODS: The authors report on the use of immunosuppressants (cyclosporin A [CSA] and low-dose oral methotrexate [MTX] given continuously) and cytotoxic agents in the treatment of 29 patients with T-cell LGL leukemia age over the past 20 years.
  • The median time to response for both agents was 1 month.
  • An ORR of 67% (all CHR) was attained with pentostatin (n = 4 patients); recurrences developed after a median of 4.6 years.
  • Successful retreatment with pentostatin was possible but with increasing drug resistance.
  • Alemtuzumab induced a PR in 1 patient who had refractory disease.
  • CONCLUSIONS: Both MTX and CSA were efficacious in the treatment of T-cell LGL leukemia but generally required long-term maintenance therapy.
  • The authors highlight the risks of second malignancies and persistence of bone marrow disease.
  • Although MTX and CSA were effective as first-line therapy, alemtuzumab and pentostatin merit further investigation, particularly for refractory disease.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Leukemia, Lymphoid / drug therapy. Leukemia, T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclophosphamide / therapeutic use. Cyclosporine / therapeutic use. Databases as Topic. Female. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Pentostatin / therapeutic use. Retrospective Studies

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • [ErratumIn] Cancer. 2006 Dec 1;107(11):2744
  • (PMID = 16795070.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 395575MZO7 / Pentostatin; 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 41
  •  go-up   go-down


9. Allegra A, Alonci A, Bellomo G, Quartarone E, D'Angelo A, Rizzotti P, Granata A, Caterina M: Fludarabine based treatment caused improvement of anemia in a patient with T-cell LGL leukemia despite evidence of the persistence of the abnormal T-cell clone. Leuk Lymphoma; 2008 Oct;49(10):2006-8
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine based treatment caused improvement of anemia in a patient with T-cell LGL leukemia despite evidence of the persistence of the abnormal T-cell clone.
  • [MeSH-major] Anemia / drug therapy. Leukemia, T-Cell / complications. Vidarabine / analogs & derivatives
  • [MeSH-minor] Aged. Clone Cells / pathology. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Leuk Lymphoma. 2009 Dec;50(12):2101. Alessandro, Allegra [corrected to Allegra, Alessandro]
  • (PMID = 18661392.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


10. Osuji N, Del Giudice I, Matutes E, Morilla A, Owusu-Ankomah K, Morilla R, Dunlop A, Catovksy D: CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab. Leuk Lymphoma; 2005 May;46(5):723-7
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
  • Few reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature.
  • Using semi-quantitative 2- and 3-color flow cytometry, we documented the expression of CD52 in 100% of abnormal cells in T-cell LGL leukemia (n = 11) and natural killer (NK) cell LGL leukemia (n = 2), and showed no significant difference in CD52 expression between T-cell prolymphocytic leukemia (PLL) and T-cell LGL leukemia.
  • Higher CD52 expression has been noted in responders to alemtuzumab in T-cell PLL and in chronic lymphocytic leukemia (CLL), a B-cell disorder.
  • The strong and consistent expression of CD52 shown here highlights the potential role of alemtuzumab in the treatment of refractory T-cell LGL leukemia and possibly aggressive NK cell leukemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / biosynthesis. Antigens, Neoplasm / biosynthesis. Antineoplastic Agents / therapeutic use. Glycoproteins / biosynthesis. Leukemia, Lymphoid / drug therapy. Leukemia, Lymphoid / immunology. Leukemia, T-Cell / drug therapy

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019510.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


11. Osuji N, Matutes E, Wotherspoon A, Catovsky D: Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment. Leuk Res; 2005 Feb;29(2):225-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment.
  • Leukemia treatment strives to eradicate the malignant clone.
  • With T-cell large granular lymphocytic (LGL) leukemia, the onus of treatment appears to be modification of the disease rather than eradication of the clone.
  • We describe a case of T-cell LGL leukemia where aggressive, eradicative type therapy proved ineffective.
  • The patient achieved hematological response to low dose oral methotrexate after failing to respond to and/or tolerate eight previous treatments including CAMPATH-1H and peripheral blood stem cell transplantation.
  • We highlight the resistant nature of the LGL clone and discuss the relative merits of immunomodulatory type therapy in this disease.
  • [MeSH-major] Immunosuppressive Agents / pharmacology. Leukemia, T-Cell / drug therapy. Methotrexate / pharmacology. T-Lymphocytes / drug effects
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Humans. Immunotherapy / methods. Male. Peripheral Blood Stem Cell Transplantation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2005 Feb;29(2):123-5 [15607357.001]
  • (PMID = 15607372.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Immunosuppressive Agents; 3A189DH42V / alemtuzumab; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Sokol L, Loughran TP Jr: Large granular lymphocyte leukemia. Curr Hematol Malig Rep; 2007 Oct;2(4):278-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocyte leukemia.
  • Clonal diseases of large granular lymphocytes (LGLs) represent a spectrum of clinically rare lymphoproliferative malignancies arising from either mature T-cell (CD3(+)) or natural killer (NK)-cell (CD3(-)) lineages.
  • The clinical behavior of these disorders ranges from indolent to very aggressive.
  • Patients with symptomatic indolent T-cell or NK-cell LGL leukemia are usually treated with immunosuppressive therapies; in contrast, aggressive T-cell or NK-cell LGL leukemias require intensive chemotherapy regimens.
  • Novel targeted therapies are currently being tested in clinical studies.
  • [MeSH-major] Leukemia, Large Granular Lymphocytic
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Clinical Trials as Topic. Combined Modality Therapy. Disease Progression. Female. Humans. Immunophenotyping. Killer Cells, Natural / pathology. Leukemia, T-Cell / complications. Leukemia, T-Cell / epidemiology. Leukemia, T-Cell / immunology. Leukemia, T-Cell / pathology. Leukemia, T-Cell / therapy. Male. Middle Aged. Myelodysplastic Syndromes / pathology. Neutropenia / etiology. Opportunistic Infections / etiology. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:63-79 [15561677.001]
  • [Cites] Am J Hematol. 2007 Jun;82(6):481-5 [17205534.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4771-7 [9845544.001]
  • [Cites] Cancer Control. 1998 Jan;5(1):25-33 [10761014.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):801-6 [11843812.001]
  • [Cites] Acta Haematol. 2000;104(2-3):110-4 [11154985.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):570-8 [16795070.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):201-12 [12876669.001]
  • [Cites] Am J Hematol. 1998 Nov;59(3):252-7 [9798667.001]
  • [Cites] Oncologist. 2006 Mar;11(3):263-73 [16549811.001]
  • [Cites] Blood. 1996 Apr 1;87(7):3000-6 [8639922.001]
  • [Cites] Blood. 1998 May 1;91(9):3372-8 [9558395.001]
  • [Cites] Leuk Lymphoma. 1994 Jun;14(1-2):137-9 [7920220.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3352-3 [7538825.001]
  • [Cites] Br J Haematol. 2001 Jan;112(1):195-200 [11167802.001]
  • [Cites] Leukemia. 1995 Jul;9(7):1207-11 [7630196.001]
  • [Cites] Leukemia. 1996 Sep;10(9):1514-9 [8751472.001]
  • [Cites] Br J Haematol. 2002 Mar;116(3):598-600 [11849217.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):141-50 [17387299.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4834-40 [16484592.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Leuk Lymphoma. 1999 Jul;34(3-4):241-50 [10439361.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):1010-4 [11843843.001]
  • [Cites] Ann Intern Med. 1985 Feb;102(2):169-75 [3966754.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1282-5 [1831681.001]
  • [Cites] Br J Haematol. 1998 May;101(2):318-24 [9609528.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2721-5 [7919384.001]
  • [Cites] Bone Marrow Transplant. 2003 Jan;31(2):105-11 [12621491.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2315-21 [7522625.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1969-71 [14976065.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2164-70 [7919331.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1474-83 [8608238.001]
  • [Cites] Blood. 1997 Jan 1;89(1):256-60 [8978299.001]
  • [Cites] Arthritis Rheum. 1997 Apr;40(4):624-6 [9125243.001]
  • [Cites] Br J Haematol. 1993 Apr;83(4):589-94 [8100140.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9220-9 [15516985.001]
  • (PMID = 20425381.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  • [Number-of-references] 39
  •  go-up   go-down


13. Lamy T, Loughran TP Jr: Clinical features of large granular lymphocyte leukemia. Semin Hematol; 2003 Jul;40(3):185-95
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of large granular lymphocyte leukemia.
  • The spectrum of large granular lymphocyte (LGL) proliferations consists of four distinct entities: reactive/transient LGL expansion, chronic LGL lymphocytosis, classical indolent LGL leukemia, and aggressive LGL leukemia.
  • LGL leukemias are classified as lymphoid malignancies.
  • They are divided into CD3(+)/T-cell LGL (85% of cases) and CD3(-)/natural killer (NK) cell LGL leukemia (15% of cases).
  • Identification of LGL expansion has been improved using T-cell receptor (TCR)beta/gamma polymerase chain reaction (PCR) analysis and a combination of Vbeta and killer cell immunoglobulin-like receptor (KIR)-specific monoclonal antibodies.
  • LGL leukemias are characterized by a clonal LGL infiltration of the bone marrow, spleen, and liver.
  • T-LGL leukemias affect the elderly and display a relatively indolent behavior.
  • Approximately 60% to 70% of patients are symptomatic: recurrent infections secondary to chronic neutropenia, anemia, and autoimmune disease such as rheumatoid arthritis are the main clinical manifestations.
  • Conversely, NK LGL leukemias behave aggressively, and most patients do not respond to chemotherapy.
  • [MeSH-major] Leukemia, Lymphoid / pathology
  • [MeSH-minor] Autoimmune Diseases. Clone Cells / immunology. Clone Cells / pathology. Hematologic Diseases. Humans. Killer Cells, Natural / immunology. Killer Cells, Natural / pathology. T-Lymphocytes / immunology. T-Lymphocytes / pathology


14. Reddy LH, Ferreira H, Dubernet C, Mouelhi SL, Desmaele D, Rousseau B, Couvreur P: Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms. Anticancer Drugs; 2008 Nov;19(10):999-1006
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms.
  • In an earlier report, we demonstrated the superior anticancer efficacy of orally administered squalenoyl gemcitabine (SQdFdC) nanomedicine over its parent drug gemcitabine on rats bearing RNK-16 large granular lymphocytic (LGL) leukemia.
  • In the present communication, we investigated the mechanisms behind this observation both at the cell and tissue level.
  • The mechanisms were investigated by performing cytotoxicity, cell uptake, and biodistribution experiments.
  • In the presence of cytidine deaminase, SQdFdC nanoassemblies resisted deamination and exerted significant anticancer activity in vitro against RNK-16 LGL leukemia cells, whereas the cytotoxicity of free gemcitabine decreased by approximately 83-fold, indicating its degradation due to deamination.
  • When administered orally to rats, unlike H-gemcitabine, the H-SQdFdC absorbed slowly, but exhibited an improved pharmacokinetics and tissue distribution profile, particularly in the lymphoid organs (the major organs of metastasis).
  • The resistance to deamination, followed by the improved pharmacokinetic and tissue distribution, and greater accumulation and retention at the level of cancer cells, are the key factors for the superiority of SQdFdC nanoassemblies over free gemcitabine against RNK-16 LGL leukemia in rats.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Deoxycytidine / analogs & derivatives. Leukemia, Experimental / drug therapy. Nanomedicine. Squalene / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Animals. Cell Line, Tumor. Rats. Rats, Inbred F344

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827565.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-(N)-tris-nor-qualenoyl-gemcitabine; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 7QWM220FJH / Squalene; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


15. Greer JP, Kinney MC, Loughran TP Jr: T cell and NK cell lymphoproliferative disorders. Hematology Am Soc Hematol Educ Program; 2001;:259-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell and NK cell lymphoproliferative disorders.
  • This review covers the diagnosis and management of natural killer and peripheral T-cell lymphomas (PTCL).
  • Problems with PTCL include their rarity, representing usually 10-15% of non-Hodgkin's lymphomas in the Western Hemisphere, morphologic heterogeneity, and lack of immunophenotypic markers for clonality.
  • Kinney gives a general overview of the diagnosis of PTCL and NK cell neoplasms.
  • Emphasis will be placed on extranodal T cell and natural killer (NK) cell lymphomas such as hepatosplenic lymphoma, subcutaneous panniculitis-like lymphoma and nasal/nasal type T/NK-cell lymphoma.
  • The use of ALK gene regulation in the classification of anaplastic large cell lymphoma is also reviewed. Dr.
  • Loughran describes current understanding of the pathogenesis of large granular lymphocyte (LGL) leukemia.
  • The discussion focuses on LGL leukemia as an instructive model of dysregulated apoptosis causing both malignant and autoimmune disease.
  • Current management options and mechanisms of therapeutic response are also described. Dr.
  • Greer addresses whether PTCL should be treated differently from the more common diffuse large B cell lymphomas.
  • He discusses the therapeutic options for anaplastic large cell lymphoma (ALCL), from a conservative approach for primary cutaneous ALCL to combination chemotherapy for the highly chemosensitive ALCL expressing anaplastic lymphoma kinase.
  • He reviews therapy options for the extranodal subtypes of PTCL by drawing from series in adults, pediatrics, dermatology, and the Far East.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11722988.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 241
  •  go-up   go-down


16. Starkebaum G: Chronic neutropenia associated with autoimmune disease. Semin Hematol; 2002 Apr;39(2):121-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic neutropenia associated with autoimmune disease.
  • Chronic neutropenia with autoimmune diseases is associated mainly with rheumatoid arthritis (RA), as Felty's syndrome or large granular lymphocyte (LGL) leukemia, and with systemic lupus erythematosus (SLE).
  • Recent advances have allowed better understanding regarding the mechanism of neutropenia and improved options for treatment.
  • The role of soluble Fas-ligand (FasL) in inducing apoptosis of neutrophils has been clarified for LGL leukemia and increased neutrophil apoptosis has been described in neutropenic patients with SLE.
  • Treatments of neutropenia have included methotrexate, cyclosporine A, and granulocyte colony-stimulating factor (G-CSF) as well as granulocyte-macrophage colony-stimulating factor (GM-CSF).
  • [MeSH-minor] Antibodies, Antineutrophil Cytoplasmic / immunology. Chronic Disease. Humans. Neutropenia / drug therapy. Neutropenia / etiology. Neutropenia / immunology. Neutrophils / drug effects. Neutrophils / immunology. Neutrophils / pathology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11957195.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic
  • [Number-of-references] 58
  •  go-up   go-down


17. Ferrajoli A, Faderl S, Ravandi F, Estrov Z: The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets; 2006 Dec;6(8):671-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The JAK-STAT pathway: a therapeutic target in hematological malignancies.
  • STAT proteins mediate cell growth, differentiation, apoptosis, transformation, and other fundamental cell functions.
  • In addition constitutive activation of the JAK-STAT pathway has been reported in various types of leukemias such as acute myelogenous leukemia, T-LGL leukemia, and multiple myeloma.
  • [MeSH-major] Hematologic Neoplasms / drug therapy. Janus Kinases / antagonists & inhibitors. STAT Transcription Factors / antagonists & inhibitors. Signal Transduction / drug effects
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Histone Deacetylase Inhibitors. Humans. PPAR gamma / agonists. Protein-Tyrosine Kinases / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168672.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Histone Deacetylase Inhibitors; 0 / PPAR gamma; 0 / STAT Transcription Factors; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Janus Kinases
  • [Number-of-references] 88
  •  go-up   go-down


18. Granjo E, Lima M, Correia T, Lisboa C, Magalhães C, Cunha N, Teixeira MA, Queirós ML, Candeias J, Matutes E: Cd8(+)/V beta 5.1(+) large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2-deoxycoformycin. Hematol Oncol; 2002 Jun;20(2):87-93
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cd8(+)/V beta 5.1(+) large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2-deoxycoformycin.
  • We report a case of CD8(+)/V beta 5.1(+) T-cell large granular lymphocyte leukemia (T-LGL leukemia) presenting with mild lymphocytosis, severe autoimmune neutropenia, thrombocytopenia, polyarthritis and recurrent infections with a chronic disease course.
  • Immunophenotyping showed an expansion of CD3(+)/TCR alpha beta(+)/CD8(+bright)/CD11c(+)/CD57(-)/CD56(-) large granular lymphocytes with expression of the TCR-V beta 5.1 family.
  • Hematopoietic growth factors, high dose intravenous immunoglobulin and corticosteroids were of limited therapeutic benefit to correct the cytopenias.
  • During the disease course, the patient developed a severe cutaneous leg ulcer and bilateral vascular mammary skin lesions.
  • Treatment with 2-deoxycoformycin resulted in both clinical and hematological complete responses, including the resolution of vascular skin lesions.
  • Combined immuno-staining with relevant T-cell associated and anti-TCR-V beta monoclonal antibodies proved to be a sensitive method to assess the therapeutic effect of 2-deoxycoformicin and to evaluate the residual disease.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Antigens, CD8. Arthritis, Rheumatoid / complications. Leukemia, Lymphoid / drug therapy. Leukemia, Lymphoid / immunology. Pentostatin / therapeutic use
  • [MeSH-minor] Aged. Antigens, CD3 / analysis. Breast / blood supply. Female. Gene Rearrangement, T-Lymphocyte / immunology. Humans. Immunophenotyping. Leg Ulcer / complications. Neutropenia / complications. Receptors, Antigen, T-Cell, alpha-beta / immunology. Thrombocytopenia / complications


19. Christopoulos PD, Katsoudas S, Androulaki A, Nakopoulou L, Economopoulos T, Vlahakos DV: T-cell large granular lymphocyte leukemia presenting as end-stage renal disease: the diagnostic role of flow-cytometric and clonality analysis of the urine sediment. Clin Nephrol; 2009 Feb;71(2):198-202
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell large granular lymphocyte leukemia presenting as end-stage renal disease: the diagnostic role of flow-cytometric and clonality analysis of the urine sediment.
  • Several liver and bone marrow biopsies during that period had shown a nonspecific polyclonal T-cell infiltration, and she was administered low-dose steroids for symptomatic relief.
  • Physical examination, laboratory workup and imaging studies at presentation showed pancytopenia, hepatosplenomegaly, large symmetric kidneys with normal cortices and no evidence of obstructive uropathy, aseptic pyuria with neutrophils and lymphocytes and mild proteinuria.
  • On biopsy the renal interstitium was infiltrated by large, granular CD3+CD8+CD56-CD57+ lymphocytes, clonal by molecular analysis, which established the diagnosis of T-cell large granular lymphocyte leukemia.
  • Most urinary and peripheral blood lymphocytes bore the same T-LGL surface markers and were also clonal, as shown by flow-cytometry and PCR amplification of the T-cell receptor g-chain genes.
  • A subsequent bone marrow biopsy revealed infiltration by lymphoma cells and excluded a myelodysplastic or hemophagocytic syndrome.
  • After exclusion of an underlying EBV, CMV, HBV, HCV or HIV infection with negative serology and blood PCR the patient received one cycle of chemotherapy with cyclophosphamide, vincristine and prednisone.
  • No improvement of renal function was achieved, while complication with a prolonged pulmonary infection and severe sepsis precluded further treatment.
  • Our report indicates that the T-LGL leukemia should be considered in the differential diagnosis of renal failure with large-sized kidneys, especially when hepatosplenomegaly, pancytopenia and aseptic pyuria are also present.
  • In the latter case, flow-cytometric and clonality analysis of the urine sediment can aid in establishing a diagnosis.
  • Since renal function may deteriorate rapidly, chemotherapy should not be delayed.
  • [MeSH-major] Flow Cytometry. Kidney Failure, Chronic / diagnosis. Leukemia, Large Granular Lymphocytic / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203516.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Dearden CE, Matutes E, Catovsky D: Alemtuzumab in T-cell malignancies. Med Oncol; 2002;19 Suppl:S27-32
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab in T-cell malignancies.
  • Alemtuzumab is a humanized monoclonal antibody directed against the CD52 antigen, which is abundantly expressed on all normal and most malignant T-lymphocytes.
  • We summarize the results of our experience using alemtuzumab to treat a range of clinically aggressive, mature, post-thymic, T-cell malignancies, including T-cell prolymphocytic leukemia (T-PLL), cutaneous T-cell lymphoma (CTCL), T-cell large granular lymphocyte (T-LGL) leukemia, and human T-cell lymphotropic virus I (HTLV-I) associated adult T-cell leukemia-lymphoma (ATLL).
  • Alemtuzumab was administered at a dose of 30 mg, three times a week until maximum response.
  • Apart from first-dose reactions, which were common, treatment was well tolerated, the main complication being infection and viral reactivation associated with the prolonged lymphopenia.
  • Overall response rates were 76% (60% complete response) in 39 patients with T-PLL and 100% in 3 patients with CTCL, of duration up to 4 yr.
  • Experience in T-LGL and ATLL is limited to single cases only and further studies are required to better define the role of alemtuzumab in these subgroups.
  • Our results indicate that alemtuzumab has activity in T-cell malignancies, particularly in T-PLL and in patients with predominantly blood and bone marrow disease.
  • It may be possible to prolong response duration by the use of high-dose therapy and stem cell transplantation.
  • Alemtuzumab may also have a role in purging minimal residual disease following other chemotherapy and prior to transplantation.
  • We conclude that treatment with alemtuzumab may offer new hope to patients who otherwise have a bleak prognosis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / drug effects. Antigens, Neoplasm / drug effects. Antineoplastic Agents / therapeutic use. Glycoproteins / drug effects. Lymphoma, T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1997 Jun;97(3):669-72 [9207420.001]
  • [Cites] Blood. 1993 Aug 1;82(3):807-12 [7687895.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Blood. 1989 May 1;73(6):1431-9 [2713487.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4491-508 [9845514.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Blood. 1998 May 15;91(10):3920-6 [9573030.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3257-63 [9779699.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):617-9 [9054672.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):432-3 [8094189.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] Oncogene. 1998 Feb 12;16(6):789-96 [9488043.001]
  • [Cites] Leuk Lymphoma. 1990;2(3-4):179-93 [27456733.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • (PMID = 12180489.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Number-of-references] 18
  •  go-up   go-down


21. Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H: Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol; 2010 Jun;91(5):799-807
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
  • During follow-up of leukocyte counts in 20 consecutive patients (age range 29-81 years) treated with dasatinib, 9 patients (7 chronic myeloid leukemia in chronic phase, 2 Philadelphia chromosome-positive acute lymphoid leukemia in complete remission) developed lymphocytosis (>3,000/microl).
  • Peripheral blood smears revealed a population of large granular lymphocytes.
  • Large granular lymphocytosis (LGL) was first noted between 1 and 8 months after initiation of dasatinib, and it has persisted up to 33 months from the onset of LGL in one patient.
  • Peak numbers of large granular lymphocytes ranged from 2,915 to 17,425/microl.
  • The occurrence of LGL might interfere with achieving molecular response (MR, real-time quantification of major BCR-ABL1 mRNA less than 50 copies/microg RNA) in our small cohort; 8 (89%) of 9 patients with LGL attained MR, while only 6 (55%) of 11 patients without LGL eventually achieved MR.
  • With respect to the relationship between LGL and pleural effusion (PE), 3 (27%) of 11 patients without LGL developed PE, while 5 (56%) of 9 patients with LGL developed PE.
  • Moreover, the mean peak number of LGL was 9,215/microl, which was much higher than the mean peak number (4,635/microl) of LGL in patients without PE.
  • [MeSH-major] Leukemia, Large Granular Lymphocytic / chemically induced. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Pleural Effusion / chemically induced. Protein Kinase Inhibitors / adverse effects. Pyrimidines / adverse effects. Thiazoles / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Dasatinib. Female. Humans. Lymphocytes / pathology. Lymphocytosis / chemically induced. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] Br J Haematol. 2009 Jun;145(5):581-97 [19388927.001]
  • [Cites] Cancer. 2010 Jan 15;116(2):377-86 [19924787.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6658-61 [15615512.001]
  • [Cites] Leukemia. 2009 Oct;23(10):1698-707 [19474800.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1398-405 [19295545.001]
  • [Cites] Target Oncol. 2009 Apr;4(2):99-105 [19381453.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1200-6 [18401416.001]
  • [Cites] Cancer. 2009 Apr 1;115(7):1381-94 [19195046.001]
  • [Cites] Int J Hematol. 2009 May;89(4):482-8 [19343480.001]
  • [Cites] J Oncol Pharm Pract. 2009 Mar;15(1):17-27 [18753186.001]
  • [Cites] Blood. 2009 Aug 27;114(9):1722-3 [19713476.001]
  • [Cites] Br J Haematol. 2008 May;141(5):745-7 [18331365.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Oct 15;176(8):814-8 [17600277.001]
  • [Cites] Haematologica. 2009 Jan;94(1):135-9 [19066329.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3908-14 [17761974.001]
  • (PMID = 20405252.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  •  go-up   go-down


22. Patel AP, Ghatak SB, Patel JA: Long term survival in aggressive NK cell leukemia. Indian Pediatr; 2010 Sep;47(9):807-8
Genetic Alliance. consumer health - Aggressive NK Cell Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term survival in aggressive NK cell leukemia.
  • Aggressive natural killer cell leukemia (ANKL) is a rare type of leukemia.
  • [MeSH-major] Leukemia, Large Granular Lymphocytic / drug therapy. Leukemia, Large Granular Lymphocytic / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Humans. Male. Prognosis. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian Pediatr. 2011 Jan;48(1):79-80 [21317480.001]
  • (PMID = 21048272.001).
  • [ISSN] 0974-7559
  • [Journal-full-title] Indian pediatrics
  • [ISO-abbreviation] Indian Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


23. Ichikawa S, Fukuhara N, Yamamoto J, Suzuki M, Nakajima S, Okitsu Y, Kohata K, Onishi Y, Ishizawa K, Kameoka J, Harigae H: Successful allogeneic hematopoietic stem cell transplantation for aggressive NK cell leukemia. Intern Med; 2010;49(17):1907-10
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful allogeneic hematopoietic stem cell transplantation for aggressive NK cell leukemia.
  • Aggressive natural killer cell leukemia (ANKL) is a highly aggressive lymphoproliferative disease.
  • An appropriate therapeutic strategy for ANKL remains to be established, but a few case reports have suggested that allogeneic hematopoietic stem cell transplantation (allo-HCT) can be curative.
  • Here, we report a young woman with ANKL showing central nervous system (CNS) invasion, who has been in complete remission for more than a year after allo-HCT following two courses of intravenous chemotherapy and several rounds of intrathecal chemotherapy.
  • Intensive remission induction chemotherapy followed by conventional myeloablative allo-HCT is a promising approach for long-term remission in cases of this aggressive malignancy.
  • [MeSH-major] Leukemia, Large Granular Lymphocytic / surgery. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Brain / pathology. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / virology. Etoposide / administration & dosage. Female. Herpesvirus 4, Human / isolation & purification. Humans. Ifosfamide / administration & dosage. Injections, Spinal. Leukemic Infiltration. Methotrexate / administration & dosage. Myeloablative Agonists / therapeutic use. Prednisone / administration & dosage. Remission Induction. Subarachnoid Hemorrhage / etiology. Subarachnoid Hemorrhage / radiography. Transplantation Conditioning. Transplantation, Homologous. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Aggressive NK Cell Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20823655.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.5.1.1 / Asparaginase; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


24. Hatsumi N, Saitoh T, Yokohama A, Uchiumi H, Matsushima T, Tsukamoto N, Nojima Y, Karasawa M, Handa H, Ogawara H, Murakami H: Ribosome-lamella complex of leukemic cells in a patient with aggressive NK cell leukemia. Ultrastruct Pathol; 2002 Nov-Dec;26(6):415-7
Genetic Alliance. consumer health - Aggressive NK Cell Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ribosome-lamella complex of leukemic cells in a patient with aggressive NK cell leukemia.
  • A bone marrow specimen revealed the proliferation of leukemic cells with flower-like nuclei observed in adult T-cell leukemia.
  • A diagnosis of aggressive NK cell leukemia was made, the patient was treated with induction chemotherapy and cord blood stem cell transplantation, and he is well now.
  • [MeSH-major] Cell Nucleus / ultrastructure. Endoplasmic Reticulum / ultrastructure. Killer Cells, Natural / ultrastructure. Leukemia, T-Cell / pathology
  • [MeSH-minor] Adult. Hematopoietic Stem Cell Transplantation. Humans. Intracellular Membranes / ultrastructure. Male. Nuclear Envelope / ultrastructure. Ribosomes / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12537767.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Ino K, Masuya M, Nakamori Y, Suzuki K, Mizutani M, Sekine T, Yamaguchi M, Nakase K, Kaida K, Ogawa H, Katayama N: [Aggressive NK-cell leukemia with sustained relapse-free survival after allogeneic peripheral blood stem cell transplantation]. Rinsho Ketsueki; 2010 Apr;51(4):258-63
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aggressive NK-cell leukemia with sustained relapse-free survival after allogeneic peripheral blood stem cell transplantation].
  • A bone marrow examination showed several hemophagocytic macrophages, and a diagnosis of hemophagocytic syndrome was made.
  • A repeat bone marrow examination demonstrated that 28.4% of marrow nucleated cells were atypical lymphocytes, which were positive for CD2, CD7, CD16, CD56, and HLA-DR.
  • Clonality of these proliferating NK cells was confirmed by an analysis of EB virus terminal repeat sequence and cytogenetic analysis, and final diagnosis of aggressive NK-cell leukemia was made.
  • After induction chemotherapy consisting of dexamethasone, etoposide, ifosfamide, and L-asparaginase, the patient achieved partial remission.
  • He received allogeneic peripheral blood stem cell transplantation from his one locus mismatched son, and is alive with no evidence of disease 20 months after transplantation.
  • [MeSH-major] Killer Cells, Natural. Leukemia, Lymphoid / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Antigens, CD. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Herpesvirus 4, Human / genetics. Humans. Male. Middle Aged. Remission Induction. Terminal Repeat Sequences. Transplantation, Homologous


26. Suzuki R: Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol; 2010 Dec;92(5):697-701
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.
  • Extranodal NK/T cell lymphoma, nasal type (ENKL) with advanced stage and aggressive NK-cell leukemia (ANKL) are highly aggressive neoplasms with a dismal clinical outcome.
  • It is well known that P-glycoprotein, which is a product of MDR1 gene and related to multi-drug resistance, is expressed on tumor cells of ENKL or ANKL.
  • This is a major reason for the refractoriness to conventional chemotherapeutic regimens for malignant lymphoma containing anthracycline.
  • However, recent studies have identified that several drugs including L: -asparaginase, methotrexate and alkylators show excellent effect for these tumors.
  • ANKL needs another treatment strategy because of a systemic disease progression and extensive organ insufficiency.
  • Optimal treatment scheme using such effective agents for these unfavorable NK-cell tumors should further be explored.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Killer Cells, Natural / pathology. Leukemia, T-Cell / therapy. Lymphoma, Extranodal NK-T-Cell / drug therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Asparaginase / administration & dosage. Asparaginase / therapeutic use. Dexamethasone / administration & dosage. Drug Therapy, Combination. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Methotrexate / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Aggressive NK Cell Leukemia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):66-72 [18283711.001]
  • [Cites] Br J Haematol. 2005 Sep;130(6):860-8 [16156856.001]
  • [Cites] Br J Haematol. 2001 Jul;114(1):177-84 [11472365.001]
  • [Cites] Ann Oncol. 2010 May;21(5):1032-40 [19850638.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]
  • [Cites] Cancer Sci. 2008 May;99(5):1016-20 [18294294.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2351-6 [8635042.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):247-55 [16049916.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1207-10 [8608206.001]
  • [Cites] J Clin Oncol. 2011 Nov 20;29(33):4410-6 [21990393.001]
  • [Cites] J Orthop Sci. 1999;4(3):231-7 [10370165.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):163-7 [12953813.001]
  • [Cites] Blood. 2008 Aug 1;112(3):461-9 [18650461.001]
  • [Cites] Int J Hematol. 2003 Oct;78(3):248-50 [14604284.001]
  • [Cites] Blood. 1999 Jan 15;93(2):599-606 [9885221.001]
  • [Cites] Int J Hematol. 2001 Dec;74(4):447-50 [11794702.001]
  • [Cites] Leukemia. 2004 Apr;18(4):763-70 [14961041.001]
  • [Cites] Immunol Rev. 2006 Dec;214:56-72 [17100876.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Int J Hematol. 2003 Jul;78(1):24-31 [12894847.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):879-82 [12802930.001]
  • [Cites] Int J Hematol. 2003 Jul;78(1):18-23 [12894846.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):449-56 [9690537.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):110-6 [18701429.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1808-17 [12200697.001]
  • [Cites] Br J Haematol. 2004 Apr;125(2):117-27 [15059133.001]
  • (PMID = 21116747.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.1 / Asparaginase; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. Sokol L, Loughran TP Jr: Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas. Curr Treat Options Oncol; 2003 Aug;4(4):289-96
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas.
  • Natural killer (NK) cell leukemia and lymphoma represent rare conditions with heterogeneity of biologic behavior, prognosis, and responsiveness to therapy.
  • The initial diagnosis of NK-cell malignancies can be difficult because of the lack of immunophenotypic clonality markers, morphologic heterogeneity, and a poor correlation between cytomorphology and prognosis.
  • Therapeutic recommendations for NK-cell malignancies are derived from retrospective studies or case reports.
  • Immature NK-cell malignancies often have aggressive behavior with poor prognosis, despite administration of acute myeloid leukemia or acute lymphocytic leukemia induction chemotherapy.
  • The use of high-dose chemotherapy with stem cell rescue resulted in a prolonged survival in a small series of patients.
  • NK-cell malignancies originating from cells with mature phenotypes form a spectrum of diseases with distinct prognosis.
  • Patients with aggressive NK-cell leukemia invariably die within several months.
  • Nasal and nasal-like NK/T-cell lymphomas with limited stage disease often respond to radiation therapy alone or combination with chemotherapy and radiation therapy, with 5-year disease-free survival rates ranging from 30% to 75%.
  • Patients with T-cell large granular lymphocyte leukemia or chronic NK-cell lymphoproliferative disease of granular lymphocytes can have an indolent clinical course with long survival without therapy.
  • However, approximately 66% of patients with T-cell large granular lymphocyte leukemia require low-dose chemotherapy with methotrexate or cyclophosphamide or immunosuppressive therapy with glucocorticosteroids or cyclosporine A for symptomatic cytopenias during the course of their disease.
  • [MeSH-major] Killer Cells, Natural. Leukemia / therapy. Lymphoma / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2001 Feb;25(2):109-13 [11166825.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1116-9 [1355373.001]
  • [Cites] Acta Oncol. 1997;36(3):307-11 [9208902.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Cancer Control. 1998 Jan;5(1):25-33 [10761014.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):225-8 [11722437.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]
  • [Cites] Leuk Res. 1989;13(9):735-43 [2796381.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2351-6 [8635042.001]
  • [Cites] Bone Marrow Transplant. 1997 Jan;19(1):91-3 [9012939.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):901-6 [12153184.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Histopathology. 1995 Dec;27(6):581-3 [8838342.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1207-10 [8608206.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Bone Marrow Transplant. 1999 Jun;23(12):1321-2 [10414923.001]
  • [Cites] Br J Haematol. 1990 May;75(1):49-59 [2375924.001]
  • [Cites] Anat Pathol. 1998;3:77-145 [10389582.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Blood. 2003 Jun 15;101(12):5007-9 [12576313.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):128-30 [1967431.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):392-9 [8388175.001]
  • [Cites] Int J Hematol. 2001 Dec;74(4):447-50 [11794702.001]
  • [Cites] Radiology. 1997 Aug;204(2):467-70 [9240537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Ann Intern Med. 1985 Feb;102(2):169-75 [3966754.001]
  • [Cites] Leuk Res. 1994 Jun;18(6):423-9 [8207960.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2417-28 [9310493.001]
  • [Cites] Cancer. 1995 May 15;75(10):2474-83 [7736391.001]
  • [Cites] Br J Haematol. 1998 May;101(2):318-24 [9609528.001]
  • [Cites] Blood. 1995 May 15;85(10):2654-70 [7742523.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2721-5 [7919384.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2164-70 [7919331.001]
  • [Cites] Leuk Res. 1999 Jul;23(7):615-24 [10400182.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):821-9 [9217183.001]
  • [Cites] Blood. 1997 Jan 1;89(1):256-60 [8978299.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):449-56 [9690537.001]
  • (PMID = 12943609.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Mohan SR, Clemente MJ, Afable M, Cazzolli HN, Bejanyan N, Wlodarski MW, Lichtin AE, Maciejewski JP: Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica; 2009 Oct;94(10):1407-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.
  • BACKGROUND: T-cell large granular lymphocytic leukemia is a clonal proliferation of cytotoxic T-lymphocytes which often results in severe cytopenia.
  • Current treatment options favor chronic immunosuppression.
  • Alemtuzumab, a humanized monoclonal antibody against glycophosphatidylinositol-anchored CD52, is approved for patients refractory to therapy in other lymphoid malignancies.
  • DESIGN AND METHODS: We retrospectively examined treatment outcomes in 59 patients with CD8+ T-cell large granular lymphocytic leukemia, 41 of whom required therapy.
  • Eight patients with severe refractory cytopenia despite multiple treatment regimens had been treated with subcutaneous alemtuzumab as salvage therapy.
  • Flow cytometry was used to monitor expression of glycophosphatidylinositol-anchored CD52, CD55, and CD59 as well as to characterize T-cell clonal expansions by T-cell receptor variable beta-chain (Vbeta) repertoire.
  • RESULTS: Analysis of the effects of alemtuzumab revealed remissions with restoration of platelets in one of one patient, red blood cell transfusion independence in three of five patients and improvement of neutropenia in one of three, resulting in an overall response rate of 50% (4/8 patients).
  • Clonal large granular lymphocytes exhibited decreased CD52 expression post-therapy in patients refractory to treatment.
  • Samples of large granular lymphocytes collected prior to therapy also unexpectedly had a significant proportion of CD52-negative cells while a healthy control population had no such CD52 deficiency (p=0.026).
  • CONCLUSIONS: While alemtuzumab may be highly effective in large granular lymphocytic leukemia, prospective serial monitoring for the presence of CD52-deficient clonal cytotoxic T-lymphocytes should be a component of clinical trials investigating the efficacy of this drug.
  • CD52 deficiency may explain lack of response to alemtuzumab, and such therapy may confer a survival advantage to glycophosphatidylinositol-negative clonal cytotoxic T-lymphocytes.

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Jul 1;98(1):165-73 [11418476.001]
  • [Cites] Blood. 2001 Jul 15;98(2):483-5 [11435321.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:259-81 [11722988.001]
  • [Cites] Leuk Lymphoma. 2001 Nov-Dec;42(6):1439-43 [11911433.001]
  • [Cites] Cytotherapy. 2001;3(3):197-201 [12171726.001]
  • [Cites] Cytotherapy. 2001;3(4):261-7 [12171714.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):33-9 [12469182.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):185-95 [12876667.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):196-200 [12876668.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):785-94 [14608907.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1548-56 [14576063.001]
  • [Cites] Oncologist. 2004;9(3):247-58 [15169980.001]
  • [Cites] Br J Haematol. 2004 Jul;126(1):55-62 [15198732.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):519-25 [15314077.001]
  • [Cites] Blood. 1988 Mar;71(3):822-4 [3345349.001]
  • [Cites] Blood. 1990 Feb 1;75(3):704-8 [2297572.001]
  • [Cites] Lancet. 1992 Sep 26;340(8822):748-52 [1356177.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1487-92 [7632956.001]
  • [Cites] Br J Haematol. 1996 May;93(2):406-8 [8639439.001]
  • [Cites] Br J Rheumatol. 1996 Dec;35(12):1252-5 [9010052.001]
  • [Cites] Biochem J. 1997 Mar 15;322 ( Pt 3):919-25 [9148769.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):123-6 [9136951.001]
  • [Cites] Lancet. 1999 Nov 13;354(9191):1691-5 [10568572.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):670-3 [10583274.001]
  • [Cites] Blood Rev. 1999 Dec;13(4):230-40 [10741898.001]
  • [Cites] Arthritis Rheum. 2000 Apr;43(4):834-43 [10765928.001]
  • [Cites] Blood. 2000 May 15;95(10):3219-22 [10807792.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):969-71 [11298593.001]
  • [Cites] J Clin Pathol. 1998 Sep;51(9):672-5 [9930071.001]
  • [Cites] Leukemia. 1999 Feb;13(2):230-40 [10025897.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):148-53 [10520035.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1636-43 [15902303.001]
  • [Cites] Leuk Lymphoma. 2005 May;46(5):723-7 [16019510.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2769-80 [15914562.001]
  • [Cites] Cytometry B Clin Cytom. 2006 Mar;70(2):71-81 [16493662.001]
  • [Cites] Haematologica. 2006 May;91(5 Suppl):ECR13 [16709521.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 5):S44-52 [16720203.001]
  • [Cites] Transplantation. 2006 Nov 27;82(10):1342-51 [17130784.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7174-9 [17145843.001]
  • [Cites] Hematology. 2006 Aug;11(4):245-56 [17178663.001]
  • [Cites] Leuk Res. 2007 Jul;31(7):939-45 [17045649.001]
  • [Cites] Immunity. 2007 Oct;27(4):670-84 [17950003.001]
  • [Cites] J Neurol. 2008 Feb;255(2):231-8 [18283404.001]
  • [Cites] Medicine (Baltimore). 1987 Sep;66(5):397-405 [3626848.001]
  • [CommentIn] Haematologica. 2009 Oct;94(10):1341-5 [19794080.001]
  • (PMID = 19794084.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113972; United States / NCRR NIH HHS / RR / U54 RR019397; United States / NCRR NIH HHS / RR / U54 RR 019397
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ PMC2754957
  •  go-up   go-down


29. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K: Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci; 2008 May;99(5):1016-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
  • Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are rare, and their standard therapy has not been established.
  • They are Epstein-Barr virus-associated lymphoid malignancies, and tumor cells express P-glycoprotein leading to multidrug resistance of the disease.
  • To develop an efficacious chemotherapeutic regimen, we conducted a dose-escalation feasibility study of a new chemotherapeutic regimen, SMILE, comprising the steroid dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide.
  • Etoposide shows both in vitro and in vivo efficacy for Epstein-Barr virus-associated lymphoproliferative disorders.
  • Eligible patients had newly diagnosed stage IV, relapsed or refractory diseases after first-line chemotherapy, were 15-69 years of age, and had satisfactory performance scores (0-2).
  • At level 1, six patients with extranodal NK/T-cell lymphoma, nasal type, were enrolled.
  • Their disease status was newly diagnosed stage IV (n = 3), first relapse (n = 2), and primary refractory (n = 1).
  • All of the first three patients developed dose-limiting toxicities, and one of them died of sepsis with grade 4 neutropenia.
  • Two out of three additional patients developed dose-limiting toxicities that were all manageable and transient.
  • Although its safety and efficacy require further evaluation, we recommend a SMILE chemotherapy dose level of 1 for further clinical studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphoid / drug therapy. Lymphoma, Extranodal NK-T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Asparaginase / administration & dosage. Asparaginase / therapeutic use. Dexamethasone / administration & dosage. Dexamethasone / therapeutic use. Etoposide / administration & dosage. Etoposide / therapeutic use. Humans. Ifosfamide / administration & dosage. Ifosfamide / therapeutic use. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294294.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.1 / Asparaginase; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


30. Guo XN, Wang CY, Wang Y, Xu SR, Ren JH, Lin FR, Yao EG: [Blastic natural killer cell leukemia--one case report and review of literature]. Zhonghua Xue Ye Xue Za Zhi; 2003 Jul;24(7):362-4
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Blastic natural killer cell leukemia--one case report and review of literature].
  • OBJECTIVE: To report a case of blastic natural killer cell leukemia with an aggressive clinical course.
  • METHODS: The characteristics of blastic NK cell leukemia and its treatment were discussed with review of literatures.
  • RESULTS: After combination chemotherapy and spinal cord segmental radiotherapy, the patient entered hematological remission, but the extramedullary lesion remained unchanged.
  • CONCLUSION: Blastic NK cell leukemia has an aggressive clinical course with poor response to treatment and unfavorable prognosis.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Lymphoid / pathology. Leukemic Infiltration
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12941191.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


31. Malani AK, Gupta C, Rangineni R, Singh J, Ammar H: Concomitant presentation of acute myeloid leukemia with T-cell large granular lymphocytic leukemia. Acta Oncol; 2007;46(2):247-9
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant presentation of acute myeloid leukemia with T-cell large granular lymphocytic leukemia.
  • T-cell large granular lymphocyte leukemia (T-LGL) also known as T-cell chronic lymphocytic leukemia is rare and comprises a small minority of all small lymphocytic leukemias.
  • The concomitant presentation of T-LGL with acute myeloid leukemia (AML) has not been previously reported.
  • We present an elderly gentleman with concomitant T-LGL and AML (non-M3) diagnosed by a combination of morphologic evaluation, immunophenotyping by flow cytometry, and T-cell gene rearrangement studies.
  • The patient was managed with combination AML chemotherapy.
  • He remains alive and well seven months after initial diagnosis.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Leukemia, Prolymphocytic, T-Cell / diagnosis
  • [MeSH-minor] Acute Disease. Aged, 80 and over. Antigens, CD / analysis. Flow Cytometry. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453377.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Number-of-references] 17
  •  go-up   go-down


32. Dearden C: The role of alemtuzumab in the management of T-cell malignancies. Semin Oncol; 2006 Apr;33(2 Suppl 5):S44-52
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of alemtuzumab in the management of T-cell malignancies.
  • T-cell malignancies are rare, making up 10% to 15% of all lymphoid neoplasms in adults.
  • They include many different types of disorders such as T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, adult T-cell leukemia/lymphoma, cutaneous T-cell lymphoma, and peripheral T-cell lymphoma, which are themselves divided into multiple subcategories.
  • Most T-cell malignancies arise as a result of chromosomal abnormalities, including T-cell receptor rearrangement anomalies.
  • Viral infections are implicated in the development of adult T-cell leukemia/lymphoma and some cases of peripheral T-cell lymphoma have been linked to Epstein-Barr virus or human immunodeficiency virus infection.
  • With the possible exception of T-cell large granular lymphocytic leukemia, which often has an indolent course, T-cell malignancies have not responded well to conventional chemotherapeutic treatment.
  • The introduction of monoclonal antibodies for the treatment of cancer has changed the outlook for patients with T-cell malignancies.
  • Recent studies with single-agent alemtuzumab, an anti-CD52 monoclonal antibody, have shown improved response rates and survival in patients with T-cell prolymphocytic leukemia and cutaneous T-cell lymphoma.
  • Preliminary data also suggest that alemtuzumab may have activity in patients with heavily pretreated peripheral T-cell lymphoma who are refractory to conventional chemotherapy.
  • Preclinical studies with mice bearing human adult T-cell leukemia/lymphoma cells suggest that alemtuzumab may have a potential therapeutic role in this setting.
  • Treatment of T-cell hematologic malignancies with alemtuzumab appears promising.
  • Earlier treatment and combination with chemotherapeutic agents may improve treatment outcome for patients with these malignancies and allow for consolidation with stem cell transplant strategies in selected patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Neoadjuvant Therapy. Remission Induction. Stem Cell Transplantation. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720203.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Number-of-references] 103
  •  go-up   go-down


33. Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, Thiéblemont C, Gaulard P, Marin B, Gachard N, Bordessoule D, Hermine O: L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol; 2009 Jan;20(1):110-6
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.
  • BACKGROUND: Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are highly aggressive diseases with a poor outcome.
  • PATIENTS AND METHODS: We report a multicentric French retrospective study of 15 patients with relapsed, refractory, or disseminated disease, treated with L-asparaginase-containing regimens in seven French centers.
  • RESULTS: All but two of the patients had an objective response to L-asparaginase-based treatment.
  • CONCLUSION: These data, although retrospective, confirm the excellent activity of L-asparaginase-containing regimens in refractory extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia.
  • Therefore, L-asparaginase-based regimen should be considered as a salvage treatment, especially for patients with disseminated disease.
  • First-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia should be tested in prospective trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701429.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase
  • [Number-of-references] 26
  •  go-up   go-down


34. Cheung MM, Chan JK, Wong KF: Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol; 2003 Jul;40(3):221-32
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias.
  • Natural killer (NK) cell neoplasms, which include extranodal NK/T-cell lymphoma (nasal and extranasal) and aggressive NK cell leukemia, are generally rare, but they are more common in people of Oriental, Mexican and South American descent.
  • These neoplasms are highly aggressive, and show a strong association with Epstein-Barr virus.
  • Extranodal NK/T-cell lymphoma most commonly affects the nasal cavity and other mucosal sites of the upper aerodigestive tract.
  • Despite the early stage of disease at presentation, overall survival is poor.
  • Patients with the extranasal form of the lymphoma often present with high-stage disease, commonly involving the skin, gastrointestinal tract, testis, and soft tissue, and the prognosis is even worse.
  • Histologically, the lymphoma can show a broad cytologic spectrum, but apoptosis, necrosis, and angioinvasion are common.
  • Based on currently available data, treatment of nasal NK/T-cell lymphoma should consist of radiotherapy, with or without multiagent chemotherapy.
  • More research is required to ascertain the role of high-dose chemotherapy with stem cell rescue and that of non-multidrug resistance-related chemotherapeutic agents.
  • Aggressive NK cell leukemia affects younger patients, who present with poor general condition, fever, and disseminated disease; they often die within a short time from systemic disease or complications such as multi-organ failure.
  • The peripheral blood and bone marrow show atypical large granular lymphocytes, which exhibit an immunophenotype similar to that of extranodal NK/T-cell lymphoma.
  • Aggressive NK cell leukemia must be distinguished from T-cell large granular lymphocyte leukemia and indolent NK cell lymphoproliferative disorder, both of which are indolent.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia / pathology. Lymphoma / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12876671.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


35. Manucha V, Zhao F, Rodgers W: Atypical lymphoid cells in cerebrospinal fluid in acute Epstein Barr virus infection: a case report demonstrating a pitfall in cerebrospinal fluid cytology. Acta Cytol; 2008 May-Jun;52(3):334-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cytologic examination of cerebrospinal fluid (CSF) continues to be important in the diagnosis of malignancies involving the leptomeninges.
  • A well-recognized pitfall is overinterpretation of the presence of atypical lymphocytes that resemble malignant lymphoid cells in the CSF.
  • A definite diagnosis is often difficult because of limited viability of cells and small sample size of CSF.
  • CASE: A 25-year-old patient with a past history of treated large granular lymphocytic leukemia and presence of a predominant population of large, atypical lymphoid cells in the CSF, giving us the impression of involvement with large cell lymphoma.
  • CONCLUSION: The presence of atypical cells in the CSF certainly warrants a detailed look at the patient's laboratory investigations and communication with the hematologist, because it may be the only specimen available for diagnosis on which therapy and prognosis is based.
  • [MeSH-major] Cerebrospinal Fluid / cytology. Cytological Techniques / methods. Epstein-Barr Virus Infections / cerebrospinal fluid. Epstein-Barr Virus Infections / pathology. Lymphocytes / pathology
  • [MeSH-minor] Adult. DNA, Viral / analysis. DNA, Viral / blood. Hepatomegaly / ultrasonography. Humans. Leukemia, Large Granular Lymphocytic / drug therapy. Lymph Nodes / pathology. Lymph Nodes / radiography. Lymphatic Diseases / pathology. Lymphatic Diseases / radiography. Male. Pleural Effusion / radiography. Splenectomy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540300.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


36. Greer JP, Mosse CA: Natural killer-cell neoplasms. Curr Hematol Malig Rep; 2009 Oct;4(4):245-52
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer-cell neoplasms.
  • The natural killer (NK)-cell neoplasms are rare, representing less than 1% of non-Hodgkin lymphoma, except in Asia and Latin America, where they represent 3% to 6%.
  • NK-cell neoplasms include immature acute leukemias; a blastic NK-cell lymphoma, which is obsolete because of its plasmacytoid dendritic-cell origin; and mature NK neoplasms, comprising extranodal NK/T-cell lymphoma (ENKL), nasal-type; aggressive NK-cell leukemia; and chronic NK-cell lymphoproliferative disorders, which are often reactive.
  • Epstein-Barr virus is usually detected in tumor cells of ENKL and aggressive NK-cell leukemia.
  • The latter two mature NK neoplasms are relatively chemoresistant because of the frequent expression of P-glycoprotein.
  • Stem cell transplantation is recommended for advanced disease, owing to a poor prognosis.
  • Novel agents, including chemotherapy, inhibitors of molecular pathways, and monoclonal antibodies, are under investigation.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia / pathology. Lymphoma / pathology. Lymphoproliferative Disorders / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cell Lineage. Cell Transformation, Neoplastic. Humans. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2006 May;79(2):179-84 [16644044.001]
  • [Cites] Br J Haematol. 2008 Oct;143(1):3-15 [18573107.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):66-72 [18283711.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(10):1402-8 [15963893.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):798-804 [1377163.001]
  • [Cites] Eur J Haematol. 2005 May;74(5):424-9 [15813917.001]
  • [Cites] Clin Adv Hematol Oncol. 2008 Dec;6(12):899-909 [19209140.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):196-204 [11230707.001]
  • [Cites] Cancer Sci. 2008 May;99(5):1016-20 [18294294.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):561-7 [16098071.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):605-10 [16827800.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):247-55 [16049916.001]
  • [Cites] Br J Haematol. 2009 Apr;145(2):173-9 [19236377.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):86-95 [14745729.001]
  • [Cites] Blood. 2008 Aug 1;112(3):461-9 [18650461.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):687-700 [17439829.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5594-600 [19805668.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1425-36 [18286525.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):141-50 [17387299.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1117-27 [15466379.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2514-22 [19293260.001]
  • [Cites] Leukemia. 2004 Apr;18(4):763-70 [14961041.001]
  • [Cites] Leuk Lymphoma. 1999 Jul;34(3-4):241-50 [10439361.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3931-7 [19029440.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2179-88 [11304770.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):579-84 [17875508.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1803-9 [11106552.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):795-9 [18756548.001]
  • [Cites] Hematology. 2007 Jun;12(3):241-4 [17558700.001]
  • [Cites] Blood. 2008 Dec 1;112(12 ):4694-8 [18791165.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(4):425-31 [16400344.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]
  • [Cites] Int J Hematol. 2008 Mar;87(2):110-7 [18256789.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] Jpn J Cancer Res. 2001 Oct;92(10):1048-56 [11676855.001]
  • [Cites] Lab Invest. 2005 Jul;85(7):874-84 [15924153.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1356-64 [19041057.001]
  • (PMID = 20425414.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 42
  •  go-up   go-down


37. Kwong YL: Natural killer-cell malignancies: diagnosis and treatment. Leukemia; 2005 Dec;19(12):2186-94
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer-cell malignancies: diagnosis and treatment.
  • Natural killer (NK)-cell malignancies are uncommon diseases.
  • Previously known as polymorphic reticulosis or angiocentric T-cell lymphomas, they are classified by the World Health Organization as NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia.
  • Pathologically, NK-cell lymphomas show a polymorphic neoplastic infiltrate with an angioinvasive and angiodestructive pattern.
  • Lymphoma cells are characteristically CD2+, CD56+ and cytoplasmic CD3epsilon+.
  • T-cell receptor gene is germline, and clonal Epstein-Barr virus (EBV) infection is almost invariably.
  • Clinically, they can be divided into nasal, non-nasal, and aggressive lymphoma/leukemia subtypes.
  • Most nasal NK-cell lymphomas present with stage I/II disease, and frontline radiotherapy is the most important key to successful treatment.
  • Many stage I/II patients treated with radiotherapy fail systemically, implying that concomitant chemotherapy may be needed.
  • Chemotherapy is indicated for advanced nasal NK-cell lymphoma, and the non-nasal and aggressive subtypes.
  • However, treatment results are unsatisfactory.
  • High-dose chemotherapy with hematopoietic stem cell transplantation may be beneficial to selected patients.
  • The International Prognostic Index and presentation EBV DNA load is of prognostic significance and may be useful in the stratification of patients for various treatment modalities.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia. Lymphoma
  • [MeSH-minor] Combined Modality Therapy. Herpesvirus 4, Human. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179910.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 83
  •  go-up   go-down


38. Ishida F, Kwong YL: Diagnosis and management of natural killer-cell malignancies. Expert Rev Hematol; 2010 Oct;3(5):593-602
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of natural killer-cell malignancies.
  • Natural killer (NK)-cell malignancies are uncommon neoplasms, which have been referred to as polymorphic reticulosis or angiocentric T-cell lymphomas in the past.
  • In the current WHO classification, they are categorized as extranodal NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia.
  • NK-cell malignancies show a geographical predilection for Asian and South American populations and are rare in the west.
  • Pathologically, NK-cell lymphomas show a polymorphic neoplastic infiltrate with angioinvasion and angiodestruction.
  • The lymphoma cells are CD2(+), cytoplasmic CD3ε(+) and CD56(+), with germline T-cell receptor gene.
  • Clinically, NK-cell lymphomas can be classified into nasal, non-nasal and aggressive lymphoma/leukemia subtypes.
  • Most nasal NK-cell lymphomas present with stage I/II disease.
  • The early use of radiotherapy, either alone or concomitantly/sequentially with chemotherapy, is the most important factor in achieving successful treatment.
  • Many stage I/II patients receiving radiotherapy alone fail systemically, so the use of chemotherapy is also considered necessary.
  • Chemotherapy is indicated for stage III/IV nasal NK-cell lymphoma, and the non-nasal and aggressive subtypes.
  • Recent regimens that incorporate the use of L-asparaginase have resulted in substantial improvements in outcome in high-risk, refractory or relapsed patients.
  • High-dose chemotherapy and hematopoietic stem-cell transplantation with autologous or allogeneic hematopoietic stem cells may be beneficial to selected patients.
  • Prognostication of patients with clinical prognostic models and presentation circulating Epstein-Barr DNA load may be useful in the stratification of patients for various treatment modalities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Asparaginase / administration & dosage. Killer Cells, Natural / drug effects. Leukemia / diagnosis. Leukemia / therapy. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / therapy
  • [MeSH-minor] Antigens, CD. Asia / epidemiology. Female. Hematopoietic Stem Cell Transplantation. Herpesvirus 4, Human. Humans. Male. Middle Aged. Prognosis. Recurrence. Severity of Illness Index. South America / epidemiology. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21083476.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


39. Okamura T, Kishimoto T, Inoue M, Honda M, Yamashita N, Wakiguchi H, Yagita M, Hosoi G, Sako M, Yasui M, Yagi K, Kawa K: Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant; 2003 Jan;31(2):105-11
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.
  • Epstein-Barr virus (EBV)-associated T/NK-cell lymphoproliferative disease (LPD) has been linked to several different disorders, including chronic active EBV infection, EBV-associated hemophagocytic syndrome, hypersensitivity to mosquito bites, hydroa vacciniforme, aggressive NK-cell leukemia, and nasal/nasal-type NK-cell lymphoma.
  • In most instances, these disorders are refractory to conventional treatments and have a poor prognosis.
  • Here, we report a new treatment strategy for EBV-associated T/NK-cell LPD, consisting of immunochemotherapy, intensive combination chemotherapy, and stem cell transplantation.
  • The five patients studied, two with T-cell and three with NK-cell LPD, lacked a human leukocyte antigen-matched, related donor, and therefore received bone marrow grafts from HLA-matched, unrelated donors.
  • The preconditioning regimen consisted of total-body irradiation (12 Gy), etoposide (900 mg/m(2)), and cyclophosphamide (120 mg/kg) or melphalan (210 mg/m(2)).
  • Thus, UBMT appears to be a reasonable option for the treatment of patients with EBV-associated T/NK-cell LPD.
  • Detection of EBV-DNA by PCR offers an important tool for assessing minimal residual disease in patients with EBV-associated T/NK-cell LPD.
  • [MeSH-major] Bone Marrow Transplantation / methods. Herpesvirus 4, Human / isolation & purification. Killer Cells, Natural / immunology. Lymphoproliferative Disorders / therapy. T-Lymphocytes / immunology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. DNA, Viral / genetics. DNA, Viral / isolation & purification. Drug Therapy, Combination. Female. Humans. Male. Polymerase Chain Reaction. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621491.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


40. Tse E, Liang RH: Natural killer cell neoplasms. Clin Lymphoma; 2004 Dec;5(3):197-201
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer cell neoplasms.
  • Lymphoid neoplasms that are derived from natural killer (NK) cells are uncommon but distinct clinicopathologic disease entities.
  • Three types have been recognized and categorized in the latest World Health Organization classification: extranodal NK cell lymphoma, nasal-type; aggressive NK cell leukemia; and blastic NK cell lymphoma.
  • All NK tumor cells express the NK cell marker CD56, but they lack the expression of surface CD3 and the rearrangement of T-cell receptor genes, which distinguish them from T-lymphoid neoplasms.
  • There is also a strong association with the Epstein-Barr virus, except in blastic NK cell lymphoma.
  • Extranodal involvement by the NK cell tumor is common, especially in the nasal cavity, the skin, and the gastrointestinal tract.
  • All 3 NK cell neoplasms are characterized by aggressive clinical course and poor response to treatment.
  • Although the optimal treatment modality remains to be determined, good initial response to combined radiation therapy and chemotherapy has been observed in localized disease.
  • Further studies in the basic biology of the NK cell and the pathology of NK cell neoplasms may shed light on the development of newer and more effective therapy.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma / immunology. Lymphoma / pathology
  • [MeSH-minor] Adult. B-Lymphocytes / immunology. Female. Humans. Male. Skin Neoplasms / immunology. Skin Neoplasms / pathology. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15636697.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Epling-Burnette PK, Bai F, Wei S, Chaurasia P, Painter JS, Olashaw N, Hamilton A, Sebti S, Djeu JY, Loughran TP: ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene; 2004 Dec 9;23(57):9220-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL).
  • Chronic NK lymphoproliferative disease of large granular lymphocytes (LDGL) is characterized by the expansion of activated CD3-, CD16+ or CD56+ lymphocytes.
  • The mechanism of survival of NK cells from LDGL patients is unknown but may be related to antigenic stimulation.
  • There is currently no standard effective therapy for LDGL, and the disease is characteristically resistant to standard forms of chemotherapy.
  • We found evidence of constitutive activation of extracellular-regulated kinase (ERK) in NK cells from 13/13 patients with NK-LDGL (one patient with aggressive and 12 patients with chronic disease).
  • Ablation of ERK activity by inhibitors or a dominant-negative form of MEK, the upstream activator of ERK, reduced the survival of patient NK cells.
  • Ras was also constitutively active in patient NK cells, and exposure of cells to the Ras inhibitor FTI2153 or to dominant-negative-Ras resulted not only in ERK inhibition but also in enhanced apoptosis in both the presence and absence of anti-Fas.
  • Therefore, we conclude that a constitutively active Ras/MEK/ERK pathway contributes to the accumulation of NK cells in patients with NK-LDGL.
  • These findings suggest that strategies to inhibit this signaling pathway may be useful for the treatment of the NK type of LDGL.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15516985.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098472; United States / NCI NIH HHS / CA / CA83947; United States / NIAID NIH HHS / AI / AI052613; United States / NCI NIH HHS / CA / CA94872; United States / NCI NIH HHS / CA / CA83146; United States / NCI NIH HHS / CA / CA90633
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


42. Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, Gondo H, Hino N, Mori H, Sugimori H, Kawa K, Oshimi K, NK-cell Tumor Study Group: Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia; 2004 Apr;18(4):763-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells.
  • Aggressive natural killer-cell leukemia (ANKL) is a rare form of large granular lymphocyte leukemia, which is characterized by a systemic proliferation of NK cells.
  • Three of 13 patients treated with chemotherapy containing anthracycline/anthraquinone attained complete remission, in contrast to none of the eight who were treated with regimens without anthracycline.
  • Although the overall prognosis was poor with a median survival of 58 days, those who attained remission showed better prognosis (P=0.005).
  • These findings suggest that ANKL is an entity of mature cytotoxic NK-cell neoplasms with distinct phenotype and disease presentations.
  • Intensive treatment for ANKL may result in a better prognosis.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Lymphoid / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anthracyclines / therapeutic use. Antigens, CD / analysis. Antineoplastic Agents / therapeutic use. Chromosome Aberrations. Female. Herpesvirus 4, Human. Humans. Immunophenotyping. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis


43. Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH: Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica; 2009 Jan;94(1):135-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
  • Dasatinib, a dual tyrosine kinase inhibitor, is known to modulate or suppress T-cell activation and proliferation.
  • We report a series of 8 patients who developed chronic peripheral lymphocytosis, identified as natural killer cells or natural killer/T-cells based on their large granular lymphocyte morphologies and CD16(+), CD56(+), CD3(-) or CD3(+) immunophenotypic profiles, out of 18 patients receiving dasatinib therapy.
  • All cases that developed large granular lymphocyte lymphocytosis achieved optimal molecular response (8/8 in large granular lymphocyte(+) patients vs. 3/10 in large granular lymphocyte(-) patients, p=0.002).
  • A (51)Cr release assay demonstrated that natural killer cell cytotoxicity has been enhanced in a case of large granular lymphocyte lymphocytosis compared to normal healthy donors, and that natural killer cell cytotoxicity in dasatinib-responders was superior to that in non-responders.
  • In summary, the present study suggests that natural killer or natural killer/T cell lineage large granular lymphocyte lymphocytosis develops in association with dasatinib therapy and that large granular lymphocyte might have a therapeutic effect on Ph(+) leukemic cells.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cell Lineage / drug effects. Killer Cells, Natural / drug effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Lymphocytosis / chemically induced. Natural Killer T-Cells / drug effects. Pyrimidines / adverse effects. Thiazoles / adverse effects
  • [MeSH-minor] Dasatinib. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2006 Feb;12(2):214-9 [16444265.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):864-72 [16393970.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3406-13 [16873671.001]
  • [Cites] Exp Hematol. 2007 Aug;35(8):1266-71 [17560008.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1366-77 [17962511.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1961-8 [10961901.001]
  • [Cites] J Immunol. 2002 Jan 15;168(2):643-50 [11777957.001]
  • [Cites] Bone Marrow Transplant. 2001 Dec;28(12):1157-60 [11803360.001]
  • [Cites] Eur J Immunol. 2002 Mar;32(3):773-82 [11870621.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2366-73 [12928383.001]
  • [Cites] J Clin Invest. 2004 Aug;114(3):379-88 [15286804.001]
  • [Cites] Nat Immun Cell Growth Regul. 1991;10(2):57-70 [1881400.001]
  • [Cites] J Biol Chem. 1995 Jul 7;270(27):16415-21 [7541798.001]
  • [Cites] Cell Immunol. 1995 Oct 15;165(2):211-6 [7553885.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2476-85 [8630414.001]
  • [Cites] Br J Haematol. 1996 May;93(2):375-85 [8639431.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2279-87 [8822949.001]
  • [Cites] J Exp Med. 1999 Oct 18;190(8):1189-96 [10523617.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):196-9 [15842042.001]
  • [Cites] J Exp Med. 2005 Jul 4;202(1):181-92 [15998796.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):5108-16 [16585609.001]
  • (PMID = 19066329.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  • [Other-IDs] NLM/ PMC2625403
  •  go-up   go-down


44. Cines DB, Liebman H, Stasi R: Pathobiology of secondary immune thrombocytopenia. Semin Hematol; 2009 Jan;46(1 Suppl 2):S2-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary immune thrombocytopenic purpura (ITP) remains a diagnosis of exclusion both from nonimmune causes of thrombocytopenia and immune thrombocytopenia that develops in the context of other disorders (secondary immune thrombocytopenia).
  • The pathobiology, natural history, and response to therapy of the diverse causes of secondary ITP differ from each other and from primary ITP, so accurate diagnosis is essential.
  • Immune thrombocytopenia can be secondary to medications or to a concurrent disease, such as an autoimmune condition (eg, systemic lupus erythematosus [SLE], antiphospholipid antibody syndrome [APS], immune thyroid disease, or Evans syndrome), a lymphoproliferative disease (eg, chronic lymphocytic leukemia or large granular T-lymphocyte lymphocytic leukemia), or chronic infection, eg, with Helicobacter pylori, human immunodeficiency virus (HIV), or hepatitis C virus (HCV).
  • Sudden and severe onset of thrombocytopenia has been observed in children after vaccination for measles, mumps, and rubella or natural viral infections, including Epstein-Barr virus, cytomegalovirus, and varicella zoster virus.
  • Proper diagnosis and treatment of the underlying disorder, where necessary, play an important role in patient management.

  • Genetic Alliance. consumer health - Immune thrombocytopenia.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - HIV InSite .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1975 Aug;64(2):180-91 [1171614.001]
  • [Cites] Arthritis Rheum. 1981 Aug;24(8):1024-36 [7284049.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):714-7 [6178333.001]
  • [Cites] Q J Med. 1991 Jul;80(291):605-12 [1946940.001]
  • [Cites] J Clin Invest. 1992 Feb;89(2):356-64 [1737832.001]
  • [Cites] Blood. 1992 Jul 1;80(1):162-9 [1611083.001]
  • [Cites] J Rheumatol. 1992 May;19(5):803-6 [1613714.001]
  • [Cites] N Engl J Med. 1992 Dec 17;327(25):1779-84 [1435932.001]
  • [Cites] Haematologica. 1992 Sep-Oct;77(5):398-401 [1483588.001]
  • [Cites] Acta Paediatr. 1993 Mar;82(3):267-70 [8495082.001]
  • [Cites] Lancet. 1993 Nov 20;342(8882):1274-5 [7694021.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2263-7 [7892259.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1719-26 [7535585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3234-8 [7536928.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1347-9 [7539157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5292-6 [7777500.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3444-51 [7780132.001]
  • [Cites] Cell. 1995 Jun 16;81(6):935-46 [7540117.001]
  • [Cites] FEBS Lett. 1995 Aug 14;370(1-2):63-8 [7544303.001]
  • [Cites] FEBS Lett. 1995 Dec 27;377(3):497-501 [8549784.001]
  • [Cites] Blood. 1996 May 15;87(10):4068-71 [8639762.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):704-6 [8652398.001]
  • [Cites] Pediatr Infect Dis J. 1996 Jan;15(1):88-90 [8684885.001]
  • [Cites] Clin Exp Rheumatol. 1995 Nov-Dec;13 Suppl 13:S39-43 [8730475.001]
  • [Cites] Blood. 1996 Jul 1;88(1):3-40 [8704187.001]
  • [Cites] Lancet. 1996 Sep 14;348(9029):719-23 [8806292.001]
  • [Cites] Blood. 2004 Jan 15;103(2):500-6 [12969975.001]
  • [Cites] Am J Med. 1996 Nov;101(5):502-7 [8948273.001]
  • [Cites] Blood. 1997 Jan 15;89(2):483-92 [9002950.001]
  • [Cites] Thromb Haemost. 1997 May;77(5):808-14 [9184382.001]
  • [Cites] Cell. 1997 Jul 11;90(1):109-19 [9230307.001]
  • [Cites] J Hepatol. 1997 Jul;27(1):127-31 [9252085.001]
  • [Cites] Br J Haematol. 1997 Aug;98(2):336-41 [9266930.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1787-98 [9292511.001]
  • [Cites] Br J Haematol. 1997 Sep;98(4):873-9 [9326182.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1479-95 [9473211.001]
  • [Cites] Gut. 1998 Mar;42(3):338-43 [9577338.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):656-8 [9674737.001]
  • [Cites] Haematologica. 1998 Jul;83(7):669-70 [9718878.001]
  • [Cites] Scand J Infect Dis. 1998;30(2):115-8 [9730294.001]
  • [Cites] Clin Exp Immunol. 1998 Sep;113(3):373-8 [9737665.001]
  • [Cites] Lancet. 1998 Sep 12;352(9131):878 [9742983.001]
  • [Cites] Ann Intern Med. 1998 Dec 1;129(11):886-90 [9867731.001]
  • [Cites] Blood. 2003 Aug 1;102(3):887-95 [12676790.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1670-7 [12738668.001]
  • [Cites] Nat Med. 2003 Sep;9(9):1123-4 [12937414.001]
  • [Cites] Br J Haematol. 2004 Jan;124(1):91-6 [14675413.001]
  • [Cites] Blood. 2004 Feb 1;103(3):890-6 [12920031.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1364-9 [14576051.001]
  • [Cites] Arch Intern Med. 2004 Feb 23;164(4):361-9 [14980986.001]
  • [Cites] Ann Intern Med. 2004 May 4;140(9):766-7 [15126268.001]
  • [Cites] J Thromb Haemost. 2004 Jun;2(6):985-92 [15140135.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):434-40 [14963696.001]
  • [Cites] Indian J Pediatr. 2004 Jun;71(6):505-7 [15226559.001]
  • [Cites] J Clin Invest. 1966 May;45(5):645-57 [5327481.001]
  • [Cites] N Engl J Med. 1974 Jan 31;290(5):249-51 [4855568.001]
  • [Cites] N Engl J Med. 1974 May 2;290(18):989-93 [4594526.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2346-53 [16304054.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):230-9 [16616070.001]
  • [Cites] Eur J Haematol. 2006 May;76(5):427-31 [16480433.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1212-8 [16380230.001]
  • [Cites] Am J Hematol. 2006 Jun;81(6):391-6 [16680753.001]
  • [Cites] J Invasive Cardiol. 2006 Jun;18(6):E173-4 [16775895.001]
  • [Cites] Clin Exp Immunol. 2006 Jul;145(1):71-80 [16792676.001]
  • [Cites] Blood. 2006 Aug 1;108(3):922-7 [16861345.001]
  • [Cites] Br J Haematol. 1982 Jul;51(3):445-50 [7104228.001]
  • [Cites] Arch Neurol. 1983 Sep;40(9):552-4 [6615286.001]
  • [Cites] J Pediatr. 1983 Dec;103(6):877-81 [6644422.001]
  • [Cites] Am J Hematol. 1983 Dec;15(4):381-90 [6606357.001]
  • [Cites] J Infect. 1984 May;8(3):274-6 [6736670.001]
  • [Cites] N Engl J Med. 1984 Sep 6;311(10):635-9 [6540841.001]
  • [Cites] Blood. 1985 Mar;65(3):584-8 [4038614.001]
  • [Cites] Ann Intern Med. 1986 Jan;104(1):47-50 [3000249.001]
  • [Cites] J Thromb Haemost. 2007 Jul;5(7):1538-44 [17470198.001]
  • [Cites] N Engl J Med. 2007 Aug 9;357(6):580-7 [17687133.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2924-30 [17548576.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):419-26 [17934346.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):511-4 [17934360.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):557-73 [17934365.001]
  • [Cites] Blood. 2007 Dec 1;110(12):3833-41 [17652264.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2227-36 [18046027.001]
  • [Cites] Thyroid. 2007 Nov;17(11):1137-42 [17887931.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4 Suppl 5):S24-34 [18096469.001]
  • [Cites] Eur J Haematol Suppl. 2008 Feb;(69):3-8 [18211567.001]
  • [Cites] Blood. 2008 Feb 1;111(3):981-6 [18223171.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):257-66 [18256550.001]
  • [Cites] Leuk Res. 2008 May;32(5):823-7 [17915315.001]
  • [Cites] Respirology. 2008 Mar;13 Suppl 1:S10-3 [18366521.001]
  • [Cites] Virol J. 2008;5:47 [18371229.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):231-7 [18628092.001]
  • [Cites] J Clin Invest. 2008 Aug;118(8):2939-49 [18654664.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1147-50 [18375792.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1078-84 [18519809.001]
  • [Cites] Hematology. 2008 Jun;13(3):181-2 [18702877.001]
  • [Cites] J Thromb Haemost. 2008 Aug;6(8):1304-12 [18489711.001]
  • [Cites] Circulation. 1997 Mar 4;95(5):1242-6 [9054855.001]
  • [Cites] Blood. 2000 Feb 1;95(3):769-75 [10648384.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):397-404 [10674912.001]
  • [Cites] Semin Hematol. 2000 Jul;37(3):239-48 [10942218.001]
  • [Cites] Stem Cells. 1996;14 Suppl 1:188-93 [11012220.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1404-6 [11100362.001]
  • [Cites] Can J Gastroenterol. 2000 Nov;14 Suppl D:60D-66D [11110614.001]
  • [Cites] Curr Gastroenterol Rep. 2001 Feb;3(1):71-8 [11177698.001]
  • [Cites] N Engl J Med. 2001 Apr 26;344(17):1286-92 [11320387.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):590-5 [11380442.001]
  • [Cites] Br J Haematol. 1986 Jul;63(3):509-16 [3089270.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] N Engl J Med. 1987 Mar 5;316(10):581-9 [3807952.001]
  • [Cites] J Clin Invest. 1987 Jul;80(1):33-40 [3597777.001]
  • [Cites] Br J Haematol. 1987 Jun;66(2):251-6 [3606961.001]
  • [Cites] Br J Haematol. 1987 Jul;66(3):337-40 [3620353.001]
  • [Cites] Eur J Haematol. 1988 May;40(5):437-41 [3378597.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(24):9763-7 [3200854.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5595-9 [2748605.001]
  • [Cites] Am J Pathol. 1989 Jun;134(6):1295-303 [2757119.001]
  • [Cites] J Rheumatol. 1989 Oct;16(10):1359-61 [2810261.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Feb;70(2):491-6 [2298861.001]
  • [Cites] Nature. 1990 Mar 29;344(6265):444-7 [2320112.001]
  • [Cites] Blood. 1990 May 15;75(10):1920-3 [2337668.001]
  • [Cites] Blood. 1991 Feb 1;77(3):481-5 [1991165.001]
  • [Cites] Blood. 1991 Jun 15;77(12):2668-76 [1710517.001]
  • [Cites] Arthritis Rheum. 2006 Aug;54(8):2558-67 [16868978.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Eur J Haematol. 2006 Dec;77(6):513-7 [17042765.001]
  • [Cites] J Thromb Haemost. 2007 Feb;5(2):369-77 [17096706.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1024-32 [8111044.001]
  • [Cites] J Lab Clin Med. 1994 Mar;123(3):415-20 [8133154.001]
  • [Cites] J Gastroenterol Hepatol. 1994 Jan-Feb;9(1):99-104 [8155875.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Thromb Haemost. 1994 May;71(5):571-5 [8091382.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):232-6 [7957808.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4203-8 [7994034.001]
  • [Cites] Leuk Lymphoma. 1994 Sep;15(1-2):187-8 [7858499.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1252-4 [11493478.001]
  • [Cites] Circulation. 2001 Aug 21;104(8):870-5 [11514371.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1760-4 [11535509.001]
  • [Cites] Cell. 2001 Sep 7;106(5):551-61 [11551503.001]
  • [Cites] Ann Intern Med. 2001 Oct 2;135(7):502-6 [11578153.001]
  • [Cites] Arch Dis Child. 2001 Mar;84(3):227-9 [11207170.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2293-300 [11588022.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2442-7 [11588041.001]
  • [Cites] Rev Clin Exp Hematol. 2001 Sep;5(3):166-200; discussion 311-2 [11703814.001]
  • [Cites] Am J Hematol. 2001 Nov;68(3):215 [11754406.001]
  • [Cites] JAMA. 2002 Jan 23-30;287(4):505-9 [11798374.001]
  • [Cites] J Rheumatol. 2002 Jan;29(1):75-83 [11824975.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):132-4 [11835350.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2054-9 [11877279.001]
  • [Cites] N Engl J Med. 2002 Mar 28;346(13):995-1008 [11919310.001]
  • [Cites] Blood. 2002 Jul 1;100(1):344-6 [12070047.001]
  • [Cites] Chest. 2002 Jul;122(1):37-42 [12114336.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1388-98 [12149222.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):2040-5 [12190174.001]
  • [Cites] Helicobacter. 2002;7 Suppl 1:17-23 [12197905.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2148-59 [12209520.001]
  • [Cites] Eur J Haematol. 2002 Nov-Dec;69(5-6):303-8 [12460235.001]
  • [Cites] Br J Clin Pharmacol. 2003 Jan;55(1):107-11 [12534647.001]
  • [Cites] Pediatr Infect Dis J. 2003 Feb;22(2):119-22 [12586974.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):574-96 [12588344.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):124-33 [12655301.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1267-76 [12774004.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1846-54 [12806618.001]
  • [Cites] Gut. 1999 Mar;44(3):336-41 [10026317.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):220-9 [10050701.001]
  • [Cites] Thromb Haemost. 1999 Mar;81(3):436-41 [10102474.001]
  • [Cites] Gut. 1999 May;44(5):754-8 [10205219.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4054-62 [15315970.001]
  • [Cites] Drug Saf. 2004;27(15):1243-52 [15588119.001]
  • [Cites] Blood. 2005 Jan 1;105(1):215-8 [15191945.001]
  • [Cites] Blood. 2005 Jan 1;105(1):131-8 [15304392.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2004 Dec;12(12):734-6 [15619340.001]
  • [Cites] Br J Haematol. 2005 Feb;128(3):366-72 [15667539.001]
  • [Cites] Chest. 2005 Feb;127(2 Suppl):53S-59S [15706031.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2443-8 [15542578.001]
  • [Cites] Am J Med. 2005 Apr;118(4):414-9 [15808140.001]
  • [Cites] Vaccine. 2005 Jun 10;23(30):3876-86 [15917108.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):818-24 [15953010.001]
  • [Cites] Am J Hematol. 2005 Jul;79(3):175-9 [15981229.001]
  • [Cites] Blood. 2005 Jul 15;106(2):572-6 [15774614.001]
  • [Cites] Platelets. 2005 Aug;16(5):307-11 [16011982.001]
  • [Cites] Hematology. 2005 Apr;10(2):101-5 [16019455.001]
  • [Cites] Eur J Haematol. 2005 Nov;75(5):417-23 [16191092.001]
  • (PMID = 19245930.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL040387-16; United States / NHLBI NIH HHS / HL / P01 HL040387; United States / NHLBI NIH HHS / HL / P01 HL040387-16
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 185
  • [Other-IDs] NLM/ NIHMS99872; NLM/ PMC2682438
  •  go-up   go-down


45. Takahashi T, Otani I, Okuda M, Inoue M, Ito K, Sakai M, Koie H, Yamaya Y, Watari T, Sato T, Kanayama K, Tokuriki M: Malignant transformation of T-cell large granular lymphocyte leukemia in a dog. J Vet Med Sci; 2007 Jun;69(6):677-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of T-cell large granular lymphocyte leukemia in a dog.
  • An 8-year-old spayed female Golden Retriever was referred to us for evaluation of mild lymphocytosis.
  • The peripheral lymphocytes were comprised of mostly large granular lymphocytes (LGLs), and flow cytometry showed that they were mostly CD3+8+ T lymphocytes.
  • Clonal rearrangement of the T-cell receptor gene was identified in the peripheral blood, and the dog was therefore diagnosed with LGL chronic leukemia.
  • The dog was subclinical without treatment until hospitalization on day 154, at which point the lymphocytes looked like lymphoblasts and the surface markers changed to CD3-8-.
  • This was regarded as malignant transformation from LGL chronic leukemia to the acute type.
  • Sequential chemotherapy was started, but the dog died on day 190.
  • Necropsy revealed tumor cell infiltration into the heart, skin, and brain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611371.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


46. Papadaki HA, Kosteas T, Gemetzi C, Alexandrakis M, Psyllaki M, Eliopoulos GD: Two patients with nonimmune chronic idiopathic neutropenia of adults developing acute myeloid leukemia with aberrant phenotype and complex karyotype but no mutations in granulocyte colony-stimulating factor receptor. Ann Hematol; 2002 Jan;81(1):50-4
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two patients with nonimmune chronic idiopathic neutropenia of adults developing acute myeloid leukemia with aberrant phenotype and complex karyotype but no mutations in granulocyte colony-stimulating factor receptor.
  • It has been suggested that some cases of nonimmune chronic idiopathic neutropenia of adults (NI-CINA) may be considered preleukemic disorders.
  • This paper describes two patients with NI-CINA who developed acute myeloid leukemia (AML) 34 and 64 months, respectively, following NI-CINA diagnosis.
  • Patient 1 presented erythema nodosum and patient 2 polyarthritis of the large joints 9 and 2 months, respectively, before AML.
  • Patient 1 had AML M4 disease associated with aberrant expression of CD7 and CD19 cell surface markers and one abnormal clone in bone marrow karyotype.
  • Patient 2 had myeloid/natural killer (NK) cell leukemia with expression of CD7 and CD56 molecules and four derivative abnormal clones in the karyotype.
  • The first patient had disease resistant to chemotherapy from the beginning of the treatment and the second following a brief complete hematological remission.
  • [MeSH-major] Leukemia, Myeloid. Neutropenia / complications. Receptors, Granulocyte Colony-Stimulating Factor / genetics
  • [MeSH-minor] Acute Disease. Adult. Chronic Disease. Female. Humans. Karyotyping. Middle Aged. Mutation

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Neutropenia idiopathic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11807637.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Receptors, Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


47. DuBois SG, Etzell JE, Matthay KK, Robbins E, Banerjee A: Pediatric acute blastic natural killer cell leukemia. Leuk Lymphoma; 2002 Apr;43(4):901-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric acute blastic natural killer cell leukemia.
  • The goal of this report is to describe a rare case of pediatric blastic natural killer (NK) cell leukemia and to compare pediatric blastic NK cell leukemia/lymphoma to other reported cases of pediatric NK cell leukemia.
  • The patient, a 9-year-old girl, presented with acute leukemia with a phenotype similar to adult blastic NK cell leukemia/lymphoma.
  • She had a complete response to ALL-directed chemotherapy, but had multiple relapses involving the cerebrospinal fluid, nasal sinus, lymph node and skin.
  • In addition to the reported case, a review of the literature identified 9 previously reported cases of NK cell leukemia in patients 18 years of age or less.
  • Cases were subdivided into blastic, acute/aggressive, and myeloid precursor NK cell leukemia based upon CD13/33 expression and morphologic characteristics.
  • Compared to pediatric acute/aggressive NK cell leukemia, children with blastic NK cell leukemia showed greater variation in age and race.
  • Pediatric blastic NK cell leukemia is a distinct clinicopathologic entity which differs from other types of pediatric NK cell leukemia.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Lymphoid / drug therapy

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12153184.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA82103
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 28
  •  go-up   go-down


48. Krick EL, Little L, Patel R, Shofer FS, Sorenmo K, Clifford CA, Baez JL: Description of clinical and pathological findings, treatment and outcome of feline large granular lymphocyte lymphoma (1996-2004). Vet Comp Oncol; 2008 Jun;6(2):102-10
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Description of clinical and pathological findings, treatment and outcome of feline large granular lymphocyte lymphoma (1996-2004).
  • Feline large granular lymphocyte (LGL) lymphoma is an uncommon, morphologically distinct variant of feline lymphoma.
  • Limited information exists in the literature regarding pathological and immunohistochemical descriptions, clinical findings, treatment and survival times.
  • The purpose of this study was to describe clinical features, treatment and outcome in feline LGL lymphoma.
  • Medical records of 45 cats with LGL lymphoma were retrospectively evaluated.
  • All cats tested for feline leukaemia virus and feline immunodeficiency virus infection were negative.
  • One complete response and six partial responses were noted in the 23 cats that received chemotherapy as their initial treatment.
  • Median survival time for cats that were treated was 57 days.
  • Based on these results, feline LGL lymphoma appears to be minimally responsive to chemotherapy and is associated with a grave prognosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cat Diseases / pathology. Lymphoma / veterinary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / veterinary
  • [MeSH-minor] Animals. Cats. Female. Immunohistochemistry / veterinary. Male. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178669.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


49. Kim D, Ko Y, Suh Y, Koo H, Huh J, Lee W: Characteristics of Epstein-Barr virus associated childhood non-Hodgkin's lymphoma in the Republic of Korea. Virchows Arch; 2005 Sep;447(3):593-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of Epstein-Barr virus associated childhood non-Hodgkin's lymphoma in the Republic of Korea.
  • To analyze the clinicopathologic characteristics of childhood non-Hodgkin's lymphoma (NHL) associated with Epstein-Barr virus (EBV), EBER in situ hybridization was performed in 80 cases of NHLs.
  • EBER-positive lymphomas account for 25% (20/80) and include NK/T-cell lymphoma (6/6), aggressive NK-cell leukemia (1/1), peripheral T cell lymphoma (5/11), diffuse large B-cell lymphoma (5/14), hydroa-like T-cell lymphoma (1/1), marginal zone B-cell lymphoma (1/2), and post-transplantation lymphoproliferative disorder (1/1).
  • Other types including 19 cases of Burkitt's lymphoma were negative.
  • Clinically, patients with EBV-positive B-cell lymphomas were cured with chemotherapy, whereas EBV-associated NK- and T cell lymphomas pursued fatal clinical course.
  • In conclusion, EBVs infected in childhood NHLs are frequently associated not only with NK- and T- cell lymphomas but also large B-cell lymphomas.
  • [MeSH-major] Epstein-Barr Virus Infections / epidemiology. Lymphoma, Non-Hodgkin / virology. Tumor Virus Infections / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2000 Dec;91(12):1233-40 [11123421.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Oct-Nov;18(7):427-42 [11594706.001]
  • [Cites] Arch Pathol Lab Med. 2002 Mar;126(3):331-5 [11860309.001]
  • [Cites] Pathol Int. 2004 Mar;54(3):151-7 [14989737.001]
  • [Cites] Cancer. 1984 Apr 15;53(8):1695-704 [6697306.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):283-8 [9042791.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):121-8 [9210717.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4244 [14623773.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Histopathology. 1994 Feb;24(2):115-22 [8181803.001]
  • [Cites] Adv Cancer Res. 1993;62:179-239 [8109318.001]
  • [Cites] Blood Rev. 1993 Dec;7(4):215-22 [8130684.001]
  • [Cites] Leuk Lymphoma. 2001 Jan;40(3-4):405-11 [11426563.001]
  • (PMID = 15991005.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / Viral Matrix Proteins; 0 / Viral Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


50. Hyakuna N, Toguchi S, Higa T, Okudaira T, Taira N, Masuda M, Kitoh T, Ohta T: Childhood blastic NK cell leukemia successfully treated with L-asparagenase and allogeneic bone marrow transplantation. Pediatr Blood Cancer; 2004 Jun;42(7):631-4
Hazardous Substances Data Bank. ASPARAGINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood blastic NK cell leukemia successfully treated with L-asparagenase and allogeneic bone marrow transplantation.
  • Blastic NK cell lymphoma/leukemia is a rare and highly malignant neoplasia in both adults and children.
  • It is characterized by lymphoblastoid morphology without cytoplasmic granules and immature NK cell immunophenotypes (CD56+, CD57-, CD16-).
  • It has predilection for extranodal organ involvement, and the prognosis of affected patients is extremely poor under the current chemotherapy.
  • We present a 14-year-old girl who was diagnosed as having blastic NK cell leukemia with mediastinal, pleural, and pericardial involvement.
  • T cell receptor (TCR) and Immunoglobulin heavy chain genes were not rearranged.
  • She received chemotherapy for acute lymphoblastic leukemia incorporating L-asparaginase (L-asp) which successfully induced complete remission.
  • Bone marrow transplantation (BMT) from her HLA-identical sibling was conducted after two courses of consolidation therapy.
  • Expression of aspargine synthetase (AS) protein in the leukemic cells at diagnosis was examined by an immunocytochemical method.
  • Induction and consolidation therapy incorporating L-asp followed by allo-BMT might be a promising treatment for child hood blastic NK cell leukemia, but more samples of the rare leukemia need to be studied before any definitive conclusions can be drawn.
  • [MeSH-major] Asparagine / therapeutic use. Bone Marrow Transplantation. Killer Cells, Natural / pathology. Leukemia, Lymphoid / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15127419.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7006-34-0 / Asparagine; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


51. Hamaguchi H, Yamaguchi M, Nagata K, Koike E, Imagunbai M, Tsurukubo Y, Yamamoto K: Aggressive NK cell lymphoma/leukemia with clonal der(3)t(1;3) (q12;p25), del(6)(q13) and del(13)(q12q14). Cancer Genet Cytogenet; 2001 Oct 15;130(2):150-4
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive NK cell lymphoma/leukemia with clonal der(3)t(1;3) (q12;p25), del(6)(q13) and del(13)(q12q14).
  • We describe a 54-year-old man with CD2, CD7, and CD56-positive but CD3, CD4, and CD8-negative aggressive NK cell lymphoma/leukemia.
  • The peripheral blood lymphoma cells contained clonal EBV-DNA by Southern blot analysis.
  • The disease was refractory to chemotherapy and the clinical course was aggressive and rapid.
  • Deletion 6q and deletion 13q have been frequently reported in NK cell lymphoma/leukemia.
  • Thus, some tumor suppressor genes involving NK cell malignancies may be present in these regions.
  • [MeSH-major] Chromosome Aberrations. Chromosome Deletion. Chromosomes, Human, Pair 13. Chromosomes, Human, Pair 3. Chromosomes, Human, Pair 6. Killer Cells, Natural / cytology. Leukemia / genetics. Lymphoma / genetics

  • Genetic Alliance. consumer health - Aggressive NK Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11675136.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD2; 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD56; 0 / Antigens, CD7; 0 / Antigens, CD8
  •  go-up   go-down


52. Kwong YL: Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia. Int J Hematol; 2010 Dec;92(5):702-7
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia.
  • Natural killer (NK) cell lymphomas and leukemias are aggressive neoplasms.
  • Clinically, they can be classified into nasal, non-nasal and lymphoma/leukemia subtypes.
  • Treatment results are unfavorable.
  • High-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) may improve patient outcome.
  • For autologous HSCT, a critical review of the literature shows that most patients with nasal NK cell lymphoma in complete remission (CR) appear to do well without HSCT.
  • Therefore, identification of patients with nasal NK cell lymphoma in CR who are at high risk of relapse may be necessary before autologous HSCT can be recommended.
  • Patients with disseminated nasal NK cell lymphoma, non-nasal NK cell lymphoma and NK cell leukemia have poor outcome with autologous HSCT.
  • Continuous efforts should be devoted to risk stratification for identifying high-risk individuals for HSCT, and defining the optimal conditioning regimen for NK cell lymphomas.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Killer Cells, Natural / pathology. Leukemia / therapy. Lymphoma / therapy
  • [MeSH-minor] Drug Therapy. Humans. Prognosis. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1322-5 [10561195.001]
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] Leuk Lymphoma. 2010 Apr;51(4):720-3 [20233057.001]
  • [Cites] Br J Haematol. 2007 Nov;139(4):532-44 [17916099.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]
  • [Cites] Br J Haematol. 2005 Sep;130(6):860-8 [16156856.001]
  • [Cites] Ann Oncol. 2003 Nov;14(11):1673-6 [14581277.001]
  • [Cites] J Clin Pathol. 2005 Apr;58(4):443-5 [15790718.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Cancer Sci. 2008 May;99(5):1016-20 [18294294.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2351-6 [8635042.001]
  • [Cites] Br J Haematol. 2010 Jul;150(2):170-8 [20507311.001]
  • [Cites] Am J Hematol. 2007 Oct;82(10):937-9 [17663389.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):561-7 [16098071.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):221-32 [12876671.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Am J Hematol. 2008 Sep;83(9):721-7 [18626884.001]
  • [Cites] Bone Marrow Transplant. 1999 Jun;23(12):1321-2 [10414923.001]
  • [Cites] Int J Hematol. 2010 Jan;91(1):107-11 [19949902.001]
  • [Cites] Blood. 1999 Jan 15;93(2):599-606 [9885221.001]
  • [Cites] Bone Marrow Transplant. 2006 May;37(9):819-24 [16547486.001]
  • [Cites] Int J Hematol. 2001 Dec;74(4):447-50 [11794702.001]
  • [Cites] Leuk Lymphoma. 2001 Nov-Dec;42(6):1297-303 [11911411.001]
  • [Cites] Bone Marrow Transplant. 1998 Jun;21(12):1279-82 [9674865.001]
  • [Cites] Hematol Oncol. 2006 Mar;24(1):28-32 [16323259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • [Cites] Leukemia. 2004 Apr;18(4):763-70 [14961041.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2186-94 [16179910.001]
  • [Cites] Int J Hematol. 2002 Feb;75(2):195-200 [11939269.001]
  • [Cites] Eur J Haematol. 2004 Feb;72(2):140-4 [14962252.001]
  • [Cites] Int J Hematol. 2009 Dec;90(5):605-10 [19936878.001]
  • [Cites] Lancet. 1996 Apr 20;347(9008):1124 [8602101.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(4):425-31 [16400344.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] Int J Hematol. 2002 Jul;76(1):94-7 [12138904.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):821-9 [9217183.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3250-4 [17545530.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1356-64 [19041057.001]
  • (PMID = 21107769.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


53. Yonescu R, Hristov AC, Ahmad A, Overby A, Thomas GH, Griffin CA: Cytogenetic characterization of natural killer cell leukemia. Cancer Genet Cytogenet; 2008 Jun;183(2):125-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic characterization of natural killer cell leukemia.
  • Natural killer (NK) cell neoplasms are rare neoplasms characterized by cells with NK characteristics.
  • Karyotype of the unstimulated peripheral blood at diagnosis was 46,XX,i(7)(q10),der(17)t(1;17)(q21;p11.1),-18,+mar[15].
  • Notably, a single cell with only an i(7q) was found, suggesting that this was the primary chromosomal abnormality in the neoplasm.
  • A final bone marrow specimen, after chemotherapy and shortly before the patient's death, showed abnormalities similar to those identified previously.
  • The abnormalities seen in chromosomes 7 and 17 are consistent with previous reports of chromosomal abnormalities in NK-cell lymphomas.
  • [MeSH-major] Chromosome Aberrations. Killer Cells, Natural / immunology. Leukemia / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Karyotyping

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Elsevier Inc.
  • (PMID = 18503833.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Kuroda J, Kimura S, Akaogi T, Hayashi H, Nishida K, Kakazu N, Abe T: Aggressive natural killer cell leukemia/lymphoma: a comprehensive cytogenetic study by spectral karyotyping. Ann Hematol; 2000 Sep;79(9):519-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive natural killer cell leukemia/lymphoma: a comprehensive cytogenetic study by spectral karyotyping.
  • Cells that had infiltrated to the bone marrow were consistent immunophenotypically and genotypically with natural killer (NK) cells.
  • The patient was diagnosed as a case of aggressive NK cell leukemia/lymphoma.
  • Combined chemotherapy was not effective and death occurred shortly after presentation.
  • The chromosomal band 14q11.2 is a recurring breakpoint in T-cell non-Hodgkin's lymphoma, and is also the locus of the delta chain of the T-cell receptor.
  • To our knowledge, t(4;14)(q12;q11.2) in T-cell or NK-cell malignancies has not been previously reported.
  • [MeSH-major] Killer Cells, Natural / metabolism. Killer Cells, Natural / pathology. Leukemia, T-Cell / genetics. Lymphoma, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11043424.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GERMANY
  •  go-up   go-down


55. Maruo T, Namikawa K, Kunihiro A, Lynch J, Shida T, Kishikawa S: Large granular lymphocytic leukaemia complicated with histiocytic sarcoma in a dog. J S Afr Vet Assoc; 2009 Dec;80(4):261-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocytic leukaemia complicated with histiocytic sarcoma in a dog.
  • Findings from the complete blood count revealed a marked lymphocytosis (113000/ml).
  • Examination of Wright-Giemsa-stained films of peripheral blood revealed the presence of large granular lymphocytes (LGL).
  • Seventy-two per cent (81360/ml) of the lymphocytes were found to be 12-17 microm in diameter, containing nuclei with mature clumped chromatin and abundant lightly basophilic cytoplasm with a variable number of fine azurophilic granules.
  • Based on these findings this case was diagnosed as LGL leukaemia.
  • As a result of multiple-agent chemotherapy, the markedly elevated levels of lymphocytes gradually decreased to 7500/ml on day 122 and the patient maintained a good quality of life for the following 3 months.
  • Shortly after diagnosis, the dog developed sudden onset of central nervous system signs and died on day 270.
  • A common outcome of canine LGL is the development of acute blast crisis or lymphoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Histiocytic Sarcoma / veterinary. Leukemia, Large Granular Lymphocytic / veterinary
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Dog Diseases. Dogs. Fatal Outcome. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458870.001).
  • [ISSN] 1019-9128
  • [Journal-full-title] Journal of the South African Veterinary Association
  • [ISO-abbreviation] J S Afr Vet Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


56. Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, Egashira M, Schuster SM, Oshimi K: Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol; 2005 Sep;130(6):860-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective apoptosis of natural killer-cell tumours by l-asparaginase.
  • We examined the effectiveness of various anti-tumour agents to natural killer (NK)-cell tumour cell lines and samples, which are generally resistant to chemotherapy, using flow cytometric terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labelling (TUNEL) assay.
  • Although NK-YS and NK-92 were highly resistant to various anti-tumour agents, l-asparaginase induced apoptosis in these two NK-cell lines.
  • NK-cell leukaemia/lymphoma and acute lymphoblastic leukaemia (ALL) samples were selectively sensitive to l-asparaginase and to doxorubicin (DXR) respectively.
  • Samples of chronic NK lymphocytosis, an NK-cell disorder with an indolent clinical course, were resistant to both drugs.
  • Our study clearly separated two major categories of NK-cell disorders and ALL according to the sensitivity to DXR and l-asparaginase.
  • We examined asparagine synthetase levels by real-time quantitative polymerase chain reaction (RQ-PCR) and immunostaining in these samples.
  • At least in nasal-type NK-cell lymphoma, there was a good correlation among asparagine synthetase expression, in vitro sensitivity and clinical response to l-asparaginase.
  • In aggressive NK-cell leukaemia, although asparagine synthetase expression was high at both mRNA and protein levels, l-asparaginase induced considerable apoptosis.
  • Furthermore, samples of each disease entity occupied a distinct area in two-dimensional plotting with asparagine synthetase mRNA level (RQ-PCR) and in vitrol-asparaginase sensitivity (TUNEL assay).
  • We confirmed rather specific anti-tumour activity of l-asparaginase against NK-cell tumours in vitro, which provides an experimental background to the clinical use of l-asparaginase for NK-cell tumours.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Asparaginase / pharmacology. Killer Cells, Natural. Leukemia, T-Cell / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Aspartate-Ammonia Ligase / biosynthesis. Aspartate-Ammonia Ligase / genetics. Cell Line, Tumor. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Humans. In Situ Nick-End Labeling. Lymphocytosis / pathology. RNA, Messenger / genetics. RNA, Neoplasm / genetics

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16156856.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 80168379AG / Doxorubicin; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


57. Gandhi J: Natural killer cell leukaemia. BMJ Case Rep; 2009;2009
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer cell leukaemia.
  • A 42-year-old white woman, who was a general practitioner referral to the medical team, presented with a 3-day history of left upper quadrant pain; an urgent private ultrasound scan had showed splenomegaly.
  • She was initially admitted with sepsis without an obvious cause but with a differential diagnosis of a haematological malignancy.
  • Her admission blood tests showed a mildly reduced white cell count and low platelets.
  • Her symptoms progressed and she developed right upper quadrant pain.
  • The infectious disease team were unable to find a cause, and haematology became involved to investigate the possibility of a haematological malignancy.
  • The patient underwent two bone marrow biopsies, a percutaneous liver biopsy and had flow cytometry of her ascitic fluid, which revealed the diagnosis of a natural killer cell leukaemia.
  • After some slight improvement on steroids, the patient was given cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab (CHOP-R) chemotherapy.
  • The patient had an initial response to chemotherapy, with reduction in ascitic volume and hepatosplenomegaly, and normalisation of her coagulation.
  • She was too weak for salvage chemotherapy, so she was put on comfort care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2427-38 [15621755.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2186-94 [16179910.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1425-36 [18286525.001]
  • [Cites] Bone Marrow Transplant. 2003 Jan;31(2):105-11 [12621491.001]
  • [Cites] Bone Marrow Transplant. 2003 Jun;31(12):1169-71 [12796798.001]
  • (PMID = 21886653.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3031875
  •  go-up   go-down


58. Bonkobara M, Saito T, Yamashita M, Tamura K, Yagihara H, Isotani M, Sato T, Washizu T: Blastic natural killer cell leukaemia in a dog--a case report. Vet J; 2007 Nov;174(3):659-62
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blastic natural killer cell leukaemia in a dog--a case report.
  • A case of canine non-T, non-B lymphoid leukaemia was determined to be of natural killer (NK) cell lineage by detecting specific expression of canine CD56 mRNA by reverse transcriptase polymerase chain reaction analysis.
  • Although NK cells are usually considered to be morphologically large granular lymphocytes, the malignant NK cells in this case were agranular and blast-like, resembling human blastic NK cell leukaemia.
  • The prognosis of human NK cell leukaemia is usually poor.
  • In this case, the dog died 10 days after initial presentation, despite chemotherapy.
  • [MeSH-major] Dog Diseases / diagnosis. Leukemia, Large Granular Lymphocytic / veterinary
  • [MeSH-minor] Animals. Antigens, CD56 / genetics. Antigens, CD56 / metabolism. Antineoplastic Agents / therapeutic use. Dogs. Doxorubicin / therapeutic use. Female. Gene Expression Regulation, Neoplastic. RNA, Messenger / genetics. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17113799.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Antineoplastic Agents; 0 / RNA, Messenger; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin
  •  go-up   go-down


59. Fortune AF, Kelly K, Sargent J, O'Brien D, Quinn F, Chadwick N, Flynn C, Conneally E, Browne P, Crotty GM, Thornton P, Vandenberghe E: Large granular lymphocyte leukemia: natural history and response to treatment. Leuk Lymphoma; 2010 May;51(5):839-45
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocyte leukemia: natural history and response to treatment.
  • Large granular lymphocyte leukemia (T-LGL) is an indolent T lymphoproliferative disorder that was difficult to diagnose with certainty until clonality testing of the T cell receptor gene became routinely available.
  • We studied the natural history and response to treatment in 25 consecutive patients with T-LGL diagnosed between 2004 and 2008 in which the diagnosis was confirmed by molecular analysis, to define an effective treatment algorithm.
  • The median age at diagnosis was 61 years (range 27-78), with a male to female ratio of 1:1.8 and presenting features of fatigue (n = 13), recurrent infections (n = 9), and/or abnormal blood counts (n = 5).
  • Thirteen patients with symptomatic disease were treated as follows: pentostatin (nine patients), cyclosporine (six patients), methotrexate (three patients), and alemtuzumab in two patients in whom pentostatin was ineffective.
  • Pentostatin was the single most effective therapy, with a response rate of 75% and minimal toxicity.
  • The overall survival (OS) and progression-free survival (PFS) 37 months from diagnosis were 80% and 52%, respectively.
  • Treatment of T-LGL should be reserved for patients with symptomatic disease, but in this series, pentostatin treatment was less toxic and more effective than cyclosporine or methotrexate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclosporine / therapeutic use. Immunosuppressive Agents / therapeutic use. Leukemia, Large Granular Lymphocytic / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / administration & dosage. Drug Therapy, Combination. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Pentostatin / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367569.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Immunosuppressive Agents; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab; 83HN0GTJ6D / Cyclosporine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


60. Ebihara Y, Manabe A, Tanaka R, Yoshimasu T, Ishikawa K, Iseki T, Hayakawa J, Maeda M, Asano S, Tsuji K: Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation. Bone Marrow Transplant; 2003 Jun;31(12):1169-71
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation.
  • The optimal treatment for natural killer (NK) cell leukemia after chronic active Epstein-Barr virus (CAEBV) infection has not been determined.
  • A 15-year-old boy presented with NK cell leukemia following CAEBV infection for 5 years.
  • The peripheral blood and BM had an increased number of CD3(-)CD56(+) large granular lymphocytes and a monoclonal integration of the EBV genome was detected.
  • Chemotherapy was not sufficiently effective to control the disease.
  • The patient is disease-free with a perfect performance status 24 months after BMT.
  • This is the first report to show that allogeneic BMT is potentially able to cure NK cell leukemia after CAEBV infection.
  • [MeSH-major] Bone Marrow Transplantation. Epstein-Barr Virus Infections / complications. Killer Cells, Natural. Leukemia, Lymphoid / etiology. Leukemia, Lymphoid / therapy


61. Morris JC, Janik JE, White JD, Fleisher TA, Brown M, Tsudo M, Goldman CK, Bryant B, Petrus M, Top L, Lee CC, Gao W, Waldmann TA: Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. Proc Natl Acad Sci U S A; 2006 Jan 10;103(2):401-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia.
  • Twelve patients with T cell large granular lymphocyte leukemia and associated hematocytopenia were treated in a phase I dose-escalation trial with the murine monoclonal antibody Mikbeta1.
  • At the doses administered in this study the antibody inhibited the actions of IL-15 on both natural killer and T cells and that of IL-2 when the intermediate-affinity IL-2 receptor was expressed.
  • Mikbeta1 treatment was not associated with significant toxicity or with the development of an immune response to the infused monoclonal antibody.
  • Nevertheless, no patients manifested a reduction in peripheral leukemic cell count or an amelioration of their hematocytopenia.
  • This latter observation may reflect the fact that the monoclonal T cell large granular lymphocyte leukemia leukemic cells of the patients did not produce IL-2 or IL-15 or require their actions for cell survival.
  • In light of the lack of toxicity and lack of immunogenicity of the antibody observed in the present study and the role for IL-15 in the pathogenesis of autoimmune diseases, clinical trials should be performed using the humanized version of Mikbeta1 in groups of patients with human T cell lymphotropic virus I-associated myelopathy/tropical spastic paraparesis, rheumatoid arthritis, multiple sclerosis and refractory celiac disease.

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1998 Jun 15;160(12):5742-8 [9637483.001]
  • [Cites] Immunity. 1998 May;8(5):591-9 [9620680.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] J Immunol. 1993 Jul 15;151(2):1075-85 [8335891.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Science. 1994 May 13;264(5161):965-8 [8178155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4940-4 [8197161.001]
  • [Cites] Science. 2000 Apr 28;288(5466):675-8 [10784451.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11445-50 [11016962.001]
  • [Cites] Blood. 2001 Jan 1;97(1):14-32 [11133738.001]
  • [Cites] Immunity. 2001 Feb;14(2):105-10 [11239443.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 3;285(5):1302-8 [11478799.001]
  • [Cites] J Exp Med. 2001 Oct 15;194(8):1187-94 [11602647.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14559-64 [11717409.001]
  • [Cites] Immunity. 2002 Nov;17(5):537-47 [12433361.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):730-45 [12949719.001]
  • [Cites] J Clin Invest. 2003 Nov;112(10):1571-80 [14617758.001]
  • [Cites] Lancet. 1975 Nov 8;2(7941):890-3 [53372.001]
  • [Cites] N Engl J Med. 1985 Sep 26;313(13):776-83 [2993886.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5394-8 [3110786.001]
  • [Cites] Medicine (Baltimore). 1987 Sep;66(5):397-405 [3626848.001]
  • [Cites] Cancer. 1987 Dec 15;60(12):2971-8 [3677021.001]
  • [Cites] Blood. 1988 Apr;71(4):1161-4 [2833327.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Mar;86(6):1982-6 [2467293.001]
  • [Cites] Blood. 1989 Jul;74(1):285-90 [2546620.001]
  • [Cites] Blood. 1990 Feb 15;75(4):935-40 [2302461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):5218-22 [2367534.001]
  • [Cites] Blood. 1990 Nov 15;76(10):2080-5 [2146981.001]
  • [Cites] J Immunol. 1994 Nov 1;153(9):4330-8 [7930631.001]
  • [Cites] EMBO J. 1995 Aug 1;14(15):3654-63 [7641685.001]
  • [Cites] Annu Rev Immunol. 1996;14:397-440 [8717520.001]
  • [Cites] J Immunol. 1997 Jan 1;158(1):452-8 [8977222.001]
  • [Cites] Nat Med. 1997 Feb;3(2):189-95 [9018238.001]
  • [Cites] N Engl J Med. 1998 Jan 15;338(3):161-5 [9428817.001]
  • [Cites] Clin Exp Immunol. 1998 Jan;111(1):193-7 [9472681.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5654-60 [9605172.001]
  • [Cites] Annu Rev Immunol. 1999;17:19-49 [10358752.001]
  • (PMID = 16387851.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Interleukin-15; 0 / Interleukin-2; 0 / Receptors, Interleukin-2
  • [Other-IDs] NLM/ PMC1326174
  •  go-up   go-down


62. Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y, Podevin P, Bouscary D, Sogni P, Blanche P, Dreyfus F: Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia; 2004 Oct;18(10):1711-6
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.
  • A link between chronic hepatitis C virus (HCV) infection and low-grade B-cell lymphomas has been suggested by epidemiological studies.
  • Marginal zone lymphomas (MZLs) including splenic lymphomas with villous lymphocytes are among the most frequently reported subgroups in the setting of chronic HCV infection.
  • In this study, we examined the effect of antiviral treatment in eight patients with HCV-associated MZL.
  • In addition, we report a case of large granular lymphocyte leukemia occurring in association with MZL and HCV, and responding to interferon and ribavirin.
  • We suggest that there is an etiologic link between HCV and antigen-driven lymphoproliferative disorders.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepacivirus / pathogenicity. Hepatitis C / drug therapy. Lymphoma, B-Cell / virology
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Interferon-alpha / therapeutic use. Male. Middle Aged. Prospective Studies. Retrospective Studies. Ribavirin / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2004 Oct;18(10):1572-5 [15284857.001]
  • (PMID = 15284859.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 49717AWG6K / Ribavirin
  •  go-up   go-down


63. Robak T: Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity. Curr Med Chem; 2009;16(18):2212-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity.
  • Chronic lymphoid leukemias include well defined mature B-cell and T-cell neoplasms with diverse natural history and specific morphological, immunophenotypic and molecular characteristics.
  • The most common adult leukemia in the Western world is chronic lymphocytic leukemia (CLL).
  • Rarer indolent lymphoid leukemias include prolymphocytic leukemia, hairy cell leukemia, large granular lymphocyte leukemia and T-cell leukemia/lymphoma.
  • Recently, several new agents have been explored and have shown promise in CLL treatment.
  • Novel therapies are being evaluated both in pre-clinical studies and in early clinical trials.
  • These treatments include new purine nucleoside analogs, antisense oligonucleotides, agents targeting the antiapoptotic Bcl-2 family of proteins, receptors involved in mediation of survival signals from the microenvironment, cyclin-dependent kinase inhibitors, protein kinase C inhibitors, tyrosine kinase inhibitors, immunomodulating drugs, new monoclonal antibodies and other agents.
  • At present, available therapies are only partially efficient and there is an obvious need to develop better strategies and new, more specific and active drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Design. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic. Drug Evaluation, Preclinical. Humans. Molecular Structure

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519388.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 230
  •  go-up   go-down


64. Gogia A, Kakar A, Byotra SP, Bhargav M: Aggressive natural killer cell leukaemia: a rare and fatal disorder. J Assoc Physicians India; 2010 Nov;58:702-4
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive natural killer cell leukaemia: a rare and fatal disorder.
  • Natural killer (NK) cell neoplasms, which include extra-nodal NK/T-cell lymphoma (nasal and extra-nasal) and aggressive NK cell leukaemia, are generally rare, but they are more common in people of Oriental, Mexican and South American descent.
  • These neoplasms are highly aggressive, and show a strong association with Epstein-Barr virus.
  • Aggressive NK cell leukaemia affects younger patients, who present with poor general condition, fever, and disseminated disease; they often die within a short time from systemic disease or complications such as multi-organ failure.
  • Aggressive NK cell leukaemia must be distinguished from T-cell large granular lymphocyte leukaemia and indolent NK cell lympho-proliferative disorder, both of which are indolent.
  • We present a case of young Asian male with aggressive NK cell leukaemia who presented with a poor general condition and disseminated disease.
  • The patient had a rapidly progressive disease and died within weeks of diagnosis.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia / pathology. Lymphoma / pathology
  • [MeSH-minor] Adult. Antibodies, Anti-Idiotypic. Biopsy. Drug Therapy. Fatal Outcome. Flow Cytometry. Herpesvirus 4, Human / immunology. Humans. Male

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21510468.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / anti-IgG
  •  go-up   go-down


65. Au WY, Lam CC, Chim CS, Pang AW, Kwong YL: Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res; 2005 Oct;29(10):1213-5
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
  • Two patients with pure red cell aplasia (PRCA) refractory to anti-thymocyte globulin, prednisolone, cyclophosphamide, fludarabine, mitoxantrone, dexamethasone and cyclosporine, were treated with alemtuzumab (anti-CD52 antibody).
  • Case 2, a 42-year-old man with PRCA due to T-cell large granular lymphocyte (T-LGL) leukaemia, achieved complete remission of the PRCA with 490 mg of alemtuzumab, although the T-LGL leukaemia responded only transiently.
  • Alemtuzumab is active in PRCA that is idiopathic or secondary to T-cell lymphoproliferative diseases.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Leukemia, T-Cell / drug therapy. Red-Cell Aplasia, Pure / drug therapy

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16111536.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antilymphocyte Serum; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab; 7S5I7G3JQL / Dexamethasone; 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


66. Ru X, Liebman HA: Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol; 2003 Oct;123(2):278-81
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
  • Acquired pure red cell aplasia (PRCA) is a rare, but significant, complication of lymphoproliferative disorders.
  • It is characterized by anaemia, absence of red cell precursors in the bone marrow and normal granulopoiesis and megakaryopoiesis.
  • We describe two patients with refractory pure red cell aplasia associated with chronic lymphocytic leukaemia (CLL) and a large granular CD8 T-lymphocytic leukaemia (LGL) respectively.
  • Both patients had failed multiple treatment regimens for PRCA and were transfusion dependent.
  • Response to treatment, as documented by a rapid increase in the reticulocyte count, occurred as early as the third infusion.
  • At the time of this report, both patients remain in complete remission with normal haemoglobin levels.
  • Alemtuzumab appears to be an effective and well-tolerated therapy for pure red blood cell aplasia associated with lymphoproliferative disorders.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Red-Cell Aplasia, Pure / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, T-Cell / complications. Male. Middle Aged. Reticulocyte Count

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14531909.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


67. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M: Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood; 2008 Feb 15;111(4):1816-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
  • Median age was 58 years (range, 25-83 years); median number of prior therapies was 2 (range, 0-10).
  • Diagnoses included chronic lymphocytic leukemia (29), T-cell prolymphocytic leukemia (3), hairy cell leukemia (1), adult T-cell leukemia/lymphoma (ATLL) (1), marginal zone leukemia (1), large granular lymphocyte leukemia (2), acute lymphoblastic leukemia (1), and T-cell lymphoma (2).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Cytomegalovirus / physiology. Cytomegalovirus Infections / prevention & control. Ganciclovir / analogs & derivatives. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Virus Activation / physiology
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Humanized. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. Female. Humans. Lymphocyte Depletion. Male. Patient Selection. T-Lymphocytes / drug effects. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2008 Sep 1;112(5):2167 [18725576.001]
  • (PMID = 18039954.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00562770
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / valganciclovir; 3A189DH42V / alemtuzumab; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


68. Robak T: Emerging drugs for rarer chronic lymphoid leukemias. Expert Opin Emerg Drugs; 2008 Mar;13(1):95-118
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs for rarer chronic lymphoid leukemias.
  • BACKGROUND: Rarer indolent lymphoid leukemias include well defined mature B-cell and T-cell neoplasm with widely varying natural history and specific morphological, immunophenotypic and molecular characteristics.
  • Among these are prolymphocytic leukemia (PLL), hairy cell leukemia (HCL) and its variants, large granular lymphocyte leukemia (LGLL) and adult T-cell leukemia/lymphoma (ATLL).
  • OBJECTIVE: To present current therapies and emerging drugs potentially useful in the treatment of rarer chronic lymphoid leukemias.
  • RESULTS/CONCLUSION: New drugs including monoclonal antibodies (mAbs), new purine analogs, small molecules targeting specific molecular targets and other agents are included.
  • Future research should focus on the novel therapeutic strategies based on the molecular pathogenic mechanisms and the development of new targeted therapies for each distinct chronic lymphoid leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drugs, Investigational / therapeutic use. Leukemia, Lymphoid / drug therapy
  • [MeSH-minor] Animals. Chronic Disease. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18321151.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational
  • [Number-of-references] 189
  •  go-up   go-down


69. Choi YL, Park JH, Kim WS, Lee DY, Lee JH, Yang JM, Lee ES: Aggressive NK-cell leukaemia associated with reactive haemophagocytic syndrome. Clin Exp Dermatol; 2006 Jan;31(1):83-5
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive NK-cell leukaemia associated with reactive haemophagocytic syndrome.
  • We report a case of aggressive NK-cell leukaemia associated with reactive haemophagocytic syndrome in a 29-year-old Korean woman who had several small purpuric patches on both thighs.
  • Laboratory tests revealed pancytopenia and deranged liver function, and atypical lymphocytes containing toxic granules were detected from peripheral blood and bone marrow.
  • Although we treated her with chemotherapy, she died 1 month later.
  • [MeSH-major] Killer Cells, Natural / immunology. Leukemia / immunology. Lymphohistiocytosis, Hemophagocytic / immunology. Lymphoma, T-Cell, Cutaneous / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309492.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


70. Alvarez-Larrán A, Villamor N, Hernández-Boluda JC, Ferrer A, Camós M, Campo E, López-Guillermo A: Blastic natural killer cell leukemia/lymphoma presenting as overt leukemia. Clin Lymphoma; 2001 Dec;2(3):178-82; discussion 183-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blastic natural killer cell leukemia/lymphoma presenting as overt leukemia.
  • Blastic natural killer (NK)-cell leukemia/lymphoma is a neoplasm of NK origin with aggressive behavior.
  • The disease affects mainly elderly people and often presents with skin lesions and overt leukemia.
  • Blastic morphology, an NK-cell immunophenotype, and lack of association with Epstein-Barr virus are the clues for the diagnosis.
  • We report herein, the case of a patient with a blastic NK-cell leukemia/lymphoma with overt leukemia at diagnosis, who achieved a complete response after CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy.
  • However, the patient relapsed a few months later and died due to disease progression.
  • Cases of blastic NK-cell leukemia/ lymphoma previously reported are briefly reviewed.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Lymphoid / pathology. Lymphoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bone Marrow / pathology. Chromosome Aberrations. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Epstein-Barr Virus Infections / complications. Fatal Outcome. Female. Humans. Immunophenotyping. Male. Middle Aged. Prednisone / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11779295.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 17
  •  go-up   go-down


71. Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socié G, Milpied N, French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC): Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica; 2007 May;92(5):627-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
  • BACKGROUND AND OBJECTIVES: High-dose chemotherapy with allogeneic stem cell transplantation (SCT) has proven to be a successful treatment for low-grade lymphoma (LGL), but is associated with considerable transplant-related mortality (TRM).
  • In an effort to reduce toxic mortality while maintaining the graft-versus-leukemia effect, allogeneic SCT has been combined with a reduced-intensity conditioning (RIC) regimen.
  • The aim of this study was to determine the outcome of patients with LGL treated with RIC allogeneic SCT.
  • DESIGN AND METHODS: This retrospective multicenter study included 73 patients with relapsed or refractory LGL allografted after a RIC regimen between 1998 and 2005 whose data were recorded in a French registry.
  • RESULTS: Patients received a median of three lines of therapy prior to RIC allogeneic SCT.
  • Prior to allografting, patients were in complete response (CR; n=21), partial response (PR; n=33) or had chemoresistant disease (n=19).
  • In patients in CR, PR and chemoresistant disease, the 3-year overall survival rates were 66%, 64% and 32%, respectively, while the 3-year event-free survival rates were 66%, 52% and 32%, respectively.
  • INTERPRETATION AND CONCLUSIONS: Although associated with significant TRM, RIC allogeneic SCT in advanced chemosensitive disease leads to long-term survival.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / statistics & numerical data. Lymphoma, Non-Hodgkin / surgery. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / therapeutic use. Antilymphocyte Serum / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Busulfan / administration & dosage. Carmustine / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Data Collection. Disease-Free Survival. Etoposide / administration & dosage. Female. France. Graft vs Host Disease / epidemiology. Graft vs Host Disease / etiology. Graft vs Leukemia Effect. Humans. Kaplan-Meier Estimate. Male. Melphalan / administration & dosage. Middle Aged. Proportional Hazards Models. Remission Induction. Retrospective Studies. Salvage Therapy. Survival Analysis. Survival Rate. T-Lymphocytes. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2007 May;92(5):580-2 [17488679.001]
  • (PMID = 17488686.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antilymphocyte Serum; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  •  go-up   go-down


72. Gill H, Liang RH, Tse E: Extranodal natural-killer/t-cell lymphoma, nasal type. Adv Hematol; 2010;2010:627401

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal natural-killer/t-cell lymphoma, nasal type.
  • The World Health Organization (WHO) classification recognizes 2 main categories of natural killer (NK) cell-derived neoplasms, namely, extranodal NK/T-cell lymphoma, nasal type, and aggressive NK-cell leukaemia.
  • Extranodal nasal NK/T-cell lymphoma is more frequent in the Far East and Latin America.
  • Early stage disease, in particular for localized lesion in the nasal region, is treated with chemotherapy and involved-field radiotherapy.
  • On the other hand, multiagent chemotherapy is the mainstay of treatment for advanced or disseminated disease.
  • The role of autologous hematopoietic stem cell transplantation is yet to be clearly defined.
  • Allogeneic hematopoietic stem cell transplantation, with the putative graft-versus-lymphoma effect, offers a potentially curative option in patients with advanced disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Apr;174(4):1141-5 [10749267.001]
  • [Cites] Leuk Lymphoma. 2010 Aug;51(8):1509-12 [20496989.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2028-32 [12727814.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2186-94 [16179910.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] Hum Pathol. 1991 Nov;22(11):1150-7 [1743700.001]
  • [Cites] Ann Hematol. 2008 Aug;87(8):613-21 [18509641.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1356-64 [19041057.001]
  • [Cites] Bone Marrow Transplant. 2009 Dec;44(11):709-14 [19767784.001]
  • [Cites] Hematol Oncol. 1990 Sep-Oct;8(5):271-81 [1979042.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5594-600 [19805668.001]
  • [Cites] Ann Oncol. 2010 May;21(5):1032-40 [19850638.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):6027-32 [19884539.001]
  • [Cites] Am J Hematol. 2010 May;85(5):362-3 [20229594.001]
  • [Cites] Histopathology. 2010 Jul;57(1):147-8 [20653786.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):814-9 [4016673.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Clin Nucl Med. 2010 Aug;35(8):571-5 [20631501.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):206-14 [15668271.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]
  • [Cites] Eur J Haematol. 2008 Jun;80(6):549-50 [18284622.001]
  • [Cites] Cancer Sci. 2008 May;99(5):1016-20 [18294294.001]
  • [Cites] Ann Hematol. 2009 Jul;88(7):647-52 [19107482.001]
  • [Cites] Br J Haematol. 2009 Oct;147(1):13-21 [19604234.001]
  • [Cites] Blood. 1995 May 15;85(10):2654-70 [7742523.001]
  • [Cites] Hum Pathol. 1994 Sep;25(9):953-60 [8088773.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2351-6 [8635042.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2095-105 [11733360.001]
  • (PMID = 21234094.001).
  • [ISSN] 1687-9112
  • [Journal-full-title] Advances in hematology
  • [ISO-abbreviation] Adv Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3018635
  •  go-up   go-down


73. Matano S, Terahata S, Nakamura S, Kobayashi K, Sugimoto T: CD56-positive acute lymphoblastic leukemia. Acta Haematol; 2005;114(3):160-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56-positive acute lymphoblastic leukemia.
  • We report a patient with lung cancer who developed CD56-positive acute lymphoblastic leukemia.
  • There were no rearrangements of T-cell receptor (TCR)-beta, TCR-gamma, or immunoglobulin heavy chain.
  • Systemic examination did not detect any tumors other than pulmonary adenocarcinoma, and the patient was diagnosed as having acute natural killer (NK) cell leukemia.
  • Chemotherapy was effective, and he achieved complete remission.
  • The course of the disease was complicated by a lung abscess, and the patient died 3 months after the diagnosis.
  • We considered that the diagnosis was blastic NK cell lymphoma/leukemia subtype.
  • However, it actually was myeloid/NK cell precursor leukemia subtype that weakly expressed CD13.
  • [MeSH-major] Antigens, CD56 / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Aged. Humans. Immunophenotyping. Killer Cells, Natural / classification. Killer Cells, Natural / immunology. Killer Cells, Natural / pathology. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 S. Karger AG, Basel
  • (PMID = 16227680.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


74. Kuroda J, Kimura S, Kobayashi Y, Jyoko N, Kamitsuji Y, Murotani Y, Fukuda W, Akaogi T, Hayashi H, Yoshikawa T, Maekawa T: Variable manifestation in natural killer cell leukaemia. Clin Lab Haematol; 2003 Aug;25(4):239-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable manifestation in natural killer cell leukaemia.
  • Natural killer (NK) cell leukaemias are a relatively rare group of haematological disorders, now entitled in the T/NK lymphoproliferative disorders in the new WHO classification.
  • However, some cases with NK malignancies still remain difficult to diagnose and differentiate into their subtypes in the absence of a distinct diagnostic hallmark, especially at initial presentation.
  • We describe herein five patients with NK leukaemias with respect to the clinical, cytological, immunological and cytogenetic characteristics, varied among each case.
  • Cytologically, two aggressive NK cell leukaemia/lymphoma (ANKL/L) cases were a morphologically hypogranular variant form.
  • Systemic chemotherapy resulted in complete remission in one ANKL/L and two blastic NK cell leukaemia/lymphoma (BNKL/L) patients; however, a good long-term outcome was achieved in only one CD4-positive BNKL/L patient with allogenic bone marrow transplantation.
  • From these findings, we conclude that comprehensive individual studies should be carried out in these patients to obtain a correct diagnosis and to design an optimal therapeutic approach.
  • [MeSH-major] Killer Cells, Natural / pathology. Neoplastic Stem Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12890163.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


75. Go RS, Tefferi A, Li CY, Lust JA, Phyliky RL: Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood; 2000 Nov 15;96(10):3644-6
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia.
  • Lymphoproliferative disease of granular T lymphocyte (T-LDGL), also known as T-cell large granular lymphocyte leukemia, is a clonal disorder of cytotoxic T lymphocytes that is clinically manifested as chronic neutropenia and anemia.
  • Morphologic evidence of increased granular lymphocytes in the peripheral blood and an excess of CD3(+)/CD8(+)/CD57(+) cells in the bone marrow were found in most cases.
  • After a median follow-up of 49 months, 5 patients had died from the disease or related complications.
  • Aplastic anemia can be a presenting manifestation of T-LDGL, and T-LDGL should be considered in the differential diagnosis of acquired aplastic anemia.
  • [MeSH-major] Anemia, Aplastic / etiology. Leukemia, T-Cell / diagnosis
  • [MeSH-minor] Adult. Aged. Bone Marrow Cells / immunology. Cyclophosphamide / administration & dosage. Cyclophosphamide / standards. Cytogenetic Analysis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunophenotyping. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / standards. Leukemia, Lymphoid / complications. Leukemia, Lymphoid / diagnosis. Leukemia, Lymphoid / drug therapy. Lymphoproliferative Disorders / complications. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / drug therapy. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / standards. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Aplastic Anemia.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11071666.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


76. Hoshino T, Tahara K, Miyawaki K, Hatsumi N, Takada S, Miyawaki S, Sakura T: [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib]. Rinsho Ketsueki; 2010 Mar;51(3):181-8
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
  • We retrospectively analyzed the clinical outcome of dasatinib in 7 patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to imatinib.
  • Three patients with chronic phase CML and two patients with Ph+ALL achieved major molecular response, however, two CML patients in accelerated phase (AP)/blast crisis (BC), did not.
  • No patients who had been intolerant to imatinib experienced the same nonhematologic toxicity following treatment with dasatinib.
  • We identified three patients who developed peripheral lymphocytosis, identified as natural killer cells or cytotoxic T-cells based on their large granular lymphocyte (LGL) morphologies and immunophenotypic profiles, out of six patients receiving dasatinib therapy.
  • All three cases that developed LGL lymphocytosis achieved optimal molecular response, two of the patients, however, had pleural effusion and CMV colitis, respectively.
  • Dasatinib inhibits off-target kinases, which may result in unexpected drug responses.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Thiazoles / administration & dosage
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colitis / chemically induced. Colitis / virology. Cytomegalovirus Infections. Dasatinib. Humans. Middle Aged. Pleural Effusion / chemically induced. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379112.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  •  go-up   go-down


77. Sternberg A, Eagleton H, Pillai N, Leyden K, Turner S, Pearson D, Littlewood T, Hatton C: Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity. Br J Haematol; 2003 Feb;120(4):699-701
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity.
  • T-cell large granular lymphocyte leukaemia (T-LGL) is a clonal disorder of T cells associated with neutropenia and anaemia.
  • The optimum treatment for severely affected patients remains to be defined.
  • Current therapies require long-term administration to maintain an effect.
  • We report the reversal of severe neutropenia and/or anaemia in four patients treated with fludarabine which has been maintained since stopping treatment.
  • The therapeutic side-effects were restricted to one episode of fever not associated with neutropenia.
  • We conclude that fludarabine is effective in T-LGL, may be given safely despite severe neutropenia and induces durable treatment-free remissions.
  • [MeSH-major] Anemia / etiology. Antineoplastic Agents / therapeutic use. Leukemia, T-Cell / drug therapy. Neutropenia / etiology. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12588360.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


78. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S: Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood; 2010 Aug 5;116(5):772-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
  • In a proportion of patients with chronic myeloid leukemia (CML) being treated with dasatinib, we recently observed large granular lymphocyte (LGL) expansions carrying clonal T-cell receptor (TCR) gamma/delta gene rearrangements.
  • To assess the prevalence and role of clonal lymphocytes in CML, we collected samples from patients (n = 34) at the time of diagnosis and during imatinib and dasatinib therapies and analyzed lymphocyte clonality with a sensitive polymerase chain reaction-based method of TCR gamma and delta genes.
  • Surprisingly, at CML diagnosis, 15 of 18 patients (83%) had a sizeable clonal, BCR-ABL1 negative lymphocyte population, which was uncommon in healthy persons (1 of 12; 8%).
  • In contrast, in a distinct population of dasatinib-treated patients, the diagnostic phase clone markedly expanded, resulting in absolute lymphocytosis in blood.
  • Most patients with LGL expansions (90%) had TCR delta rearrangements, which were uncommon in patients without an LGL expansion (10%).
  • The TCR delta clones were confined to gammadelta(+) T- or natural killer-cell compartments and the TCR gamma clones to CD4(+)/CD8(+) alphabeta(+) fractions.
  • The functional importance of clonal lymphocytes as a part of leukemia immune surveillance and the putative anergy-reversing role of dasatinib require further evaluation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Clone Cells / pathology. Killer Cells, Natural / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. T-Lymphocyte Subsets / pathology. Thiazoles / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. CD8-Positive T-Lymphocytes / chemistry. CD8-Positive T-Lymphocytes / pathology. Clonal Anergy. Cytomegalovirus / physiology. Dasatinib. Female. Fusion Proteins, bcr-abl / analysis. Fusion Proteins, bcr-abl / antagonists & inhibitors. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Imatinib Mesylate. Immunologic Surveillance. Lymphocyte Count. Male. Middle Aged. Piperazines / therapeutic use. Receptors, Antigen, T-Cell, gamma-delta / genetics. Virus Activation / drug effects. Young Adult

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 Aug 5;116(5):673-4 [20688961.001]
  • (PMID = 20413659.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  •  go-up   go-down


79. Dincol G, Diz-Kuçukkaya R, Bicakci E: T-cell large granular lymphocytic leukaemia: successful response to 2-deoxycoformycin. Neth J Med; 2008 Feb;66(2):85-7
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell large granular lymphocytic leukaemia: successful response to 2-deoxycoformycin.
  • We report a 25-year-old woman with T-cell large granular lymphocytic leukaemia presenting with severe neutropenia, anaemia and recurrent infections with a chronic disease course.
  • Immunophenotyping showed an expansion of CD3+, TCRgamma delta+, CD4-, CD5+, CD7+, CD8+, CD57+ large granular lymphocytes.
  • Clonality was demonstrated with T-gamma polymerase chain reaction analysis which revealed clonal rearrangement of the TCRgamma chain gene.
  • Finally, treatment with 2-deoxycoformycin resulted in both clinical and haemotological complete responses, despite molecular evidence of the persistence of the abnormal T-cell clone.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Large Granular Lymphocytic / drug therapy. Pentostatin / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18292613.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin
  •  go-up   go-down


80. Armor JF, Fazili J, Toubia N, Kern W, Kamble R, Kharfan-Dabaja MA: Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy. Am J Hematol; 2005 Mar;78(3):212-5
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy.
  • Non-Hodgkin lymphomas (NHL) consist of a diverse group of lymphoproliferative neoplasms with unique patterns of biology, behavior, and differing responses to therapy.
  • A rare subtype of malignancy arising from cells of putative natural killer (NK) origin is being recognized as a distinct clinicopathological entity.
  • Viruses including hepatitis C have been reported in association with various types of NHL but not the NK-cell subtype.
  • We hereby report a unique case of a patient with hepatitis C who developed hepatic NK-cell lymphoma and chronic NK-cell leukemia.
  • Interestingly, we observed clinical and radiologic remission of the neoplasm following treatment with anti-hepatitis C therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C / drug therapy. Killer Cells, Natural / pathology. Liver Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Tumor Virus Infections / pathology
  • [MeSH-minor] Humans. Interferon-alpha / therapeutic use. Male. Middle Aged. Recombinant Proteins. Remission Induction. Ribavirin / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726605.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 49717AWG6K / Ribavirin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


81. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K: Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia; 2009 Aug;23(8):1398-405
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
  • Dasatinib, a broad-spectrum tyrosine kinase inhibitor (TKI), predominantly targets BCR-ABL and SRC oncoproteins and also inhibits off-target kinases, which may result in unexpected drug responses.
  • We identified 22 patients with marked lymphoproliferation in blood while on dasatinib therapy.
  • An abrupt lymphocytosis (peak count range 4-20 x 10(9)/l) with large granular lymphocyte (LGL) morphology was observed after a median of 3 months from the start of therapy and it persisted throughout the therapy.
  • Fifteen patients had a cytotoxic T-cell and seven patients had an NK-cell phenotype.
  • All T-cell expansions were clonal.
  • Adverse effects, such as colitis and pleuritis, were common (18 of 22 patients) and were preceded by LGL lymphocytosis.
  • Responses to dasatinib were good and included complete, unexpectedly long-lasting remissions in patients with advanced leukemia.
  • In a phase II clinical study on 46 Philadelphia chromosome-positive acute lymphoblastic leukemia, patients with lymphocytosis had superior survival compared with patients without lymphocytosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Killer Cells, Natural / drug effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Lymphocytosis / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein Kinase Inhibitors / pharmacology. Pyrimidines / pharmacology. T-Lymphocyte Subsets / drug effects. T-Lymphocytes, Cytotoxic / drug effects. Thiazoles / pharmacology

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Haematol. 2016;136(4):219-228 [27656875.001]
  • (PMID = 19295545.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  •  go-up   go-down


82. Moosig F, Schoch R, Kneba M: [T-large granular lymphocyte leukaemia. An important differential diagnosis to Felty's syndrome]. Z Rheumatol; 2006 Sep;65(5):447-51
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [T-large granular lymphocyte leukaemia. An important differential diagnosis to Felty's syndrome].
  • [Transliterated title] Die T-large Granular Lymphocyte Leukämie (T-LGL-Leukämie). Eine wichtige Differenzialdiagnose zum Felty-syndrom.
  • T-Large Granular Lymphocyte (T-LGL) leukaemia is a rare clonal disease characterized by neutropenia and/or anaemia.
  • Because of its strong association with rheumatoid arthritis (RA), T-LGL leukaemia is an important differential diagnosis to Felty's syndrome.
  • This differentiation might be especially difficult since, in severe RA with extraarticular manifestations, there is often an expanded memory effector T-cell population which can hardly be separated from T-LGL leukaemia cells by means of immunophenotyping.
  • The main criterion for T-LGL leukaemia is the detection of a clonal T-cell-receptor rearrangement by PCR.
  • First-line therapy consists of weekly low-dose methotrexate.
  • There are very limited data from therapy studies.
  • The German CLL study group has initiated a protocol using parenteral low-dose methotrexate as first-line therapy and fludarabine as second-line medication.
  • [MeSH-major] Leukemia, Lymphoid / diagnosis. Leukemia, T-Cell / diagnosis
  • [MeSH-minor] Antirheumatic Agents / therapeutic use. Antiviral Agents / therapeutic use. Arthritis, Rheumatoid / diagnosis. Arthritis, Rheumatoid / drug therapy. Diagnosis, Differential. Felty Syndrome / diagnosis. Humans. Immunosuppressive Agents / therapeutic use. Methotrexate / therapeutic use. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Genetic Alliance. consumer health - Felty's Syndrome.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 2005 Aug;141(2):201-10 [15996183.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1199-200 [8562948.001]
  • [Cites] Arthritis Rheum. 1997 Jun;40(6):1106-14 [9182921.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):857-65 [12786796.001]
  • [Cites] Br J Haematol. 2003 Nov;123(4):613-20 [14616964.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4771-7 [9845544.001]
  • [Cites] Cancer Control. 1998 Jan;5(1):25-33 [10761014.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):935-41 [15958859.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):763-71 [12875995.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4609-16 [8648103.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Leuk Res. 2001 Aug;25(8):699-708 [11397476.001]
  • [Cites] Br J Rheumatol. 1996 Dec;35(12):1252-5 [9010052.001]
  • [Cites] Blood. 1998 May 1;91(9):3372-8 [9558395.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1449-53 [12149230.001]
  • [Cites] Br J Haematol. 2002 Mar;116(3):598-600 [11849217.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1861-8 [11696446.001]
  • [Cites] Leuk Res. 2005 Apr;29(4):381-7 [15725471.001]
  • [Cites] Am J Med. 1977 Apr;62(4):588-96 [192076.001]
  • [Cites] Blood. 2000 May 15;95(10):3219-22 [10807792.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):699-701 [12588360.001]
  • [Cites] Br J Haematol. 2003 Jan;120(1):93-6 [12492582.001]
  • [Cites] Ann Intern Med. 1985 Feb;102(2):169-75 [3966754.001]
  • [Cites] Orv Hetil. 1997 Aug 17;138(33):2075-80 [9304100.001]
  • [Cites] Hematol J. 2003;4(1):18-25 [12692516.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):185-95 [12876667.001]
  • [Cites] Arthritis Rheum. 2000 Apr;43(4):834-43 [10765928.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3198-204 [12480700.001]
  • [Cites] Blood. 1987 Apr;69(4):1204-10 [3103716.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):1026-36 [12648073.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):449-53 [14617004.001]
  • [Cites] Oncologist. 2004;9(3):247-58 [15169980.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2164-70 [7919331.001]
  • [Cites] Arthritis Rheum. 1997 Apr;40(4):624-6 [9125243.001]
  • [Cites] J Exp Med. 1994 Feb 1;179(2):609-18 [8294871.001]
  • [Cites] Dtsch Med Wochenschr. 1989 Jul 7;114(27):1064-8 [2525466.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):490-2 [15686456.001]
  • (PMID = 16450150.001).
  • [ISSN] 0340-1855
  • [Journal-full-title] Zeitschrift fur Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Antiviral Agents; 0 / Immunosuppressive Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 39
  •  go-up   go-down


83. Ma SY, Au WY, Chim CS, Lie AK, Lam CC, Tse E, Leung AY, Liang R, Kwong YL: Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients. Br J Haematol; 2004 Mar;124(6):754-61
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.
  • The treatment results of indolent lymphoid malignancies in Chinese are poorly reported.
  • The efficacy of FND (fludarabine 25 mg/m2/d, x3; mitoxantrone 10 mg/m2/d, x1; dexamethasone 20 mg/d, x5; monthly cycles, x6) in 95 Chinese patients with indolent B-cell malignancies (at diagnosis: 55, relapse/refractory disease: 40) and nine Chinese patients with T-cell large granular lymphocyte leukaemia (T-LGL leukaemia) (at diagnosis: two, refractory disease: seven) was evaluated.
  • For B-cell malignancies, the complete response (CR), partial response (PR) and overall response (OR) rates were 50.5%, 18% and 68.5% respectively.
  • Better results were obtained for primary versus relapse/refractory disease (CR: 60% vs. 37.5%, P = 0.03; OR: 84% vs. 47.5%, P < 0.001; median progression-free survival (PFS): 44 months vs. 22 months; 2-year PFS: 66% vs. 47%, P = 0.039; overall survival (OS): not reached vs. 32%; 2-year OS: 92% vs. 58%, P < 0.001).
  • For T-LGL leukaemia, the CR and molecular-remission rates were 56% and 67% (median follow-up: 23 months).
  • FND is an active regimen for the treatment of indolent B- and T-cell malignancies in Chinese patients, with results comparable with Western patients with similar indolent lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Prolymphocytic, T-Cell / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Asian Continental Ancestry Group. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / ethnology. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Prospective Studies. Rituximab. Survival Analysis. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15009063.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 7S5I7G3JQL / Dexamethasone; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; FND protocol
  •  go-up   go-down


84. Battiwalla M, Melenhorst J, Saunthararajah Y, Nakamura R, Molldrem J, Young NS, Barrett AJ: HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. Br J Haematol; 2003 Nov;123(3):449-53
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders.
  • T-cell large granular lymphocytic lymphoproliferative disease (T-LGL) is often associated with life-threatening cytopenias.
  • Twenty-five subjects with anaemia and/or neutropenia caused by T-LGL were treated with cyclosporin A (CSA) 5-10 mg/kg/d for at least 3 months.
  • Eighteen patients survived between 35 and 77 months after starting treatment.
  • T-LGL subtype, LGL counts after therapy, lymphocytic marrow infiltration and bone marrow cellularity did not significantly affect the probability of response.
  • We conclude that CSA is effective in inducing haematological responses in HLA-DR4-positive patients and that T-LGL is likely to have an immune pathogenesis.
  • [MeSH-major] Cyclosporine / therapeutic use. HLA-DR4 Antigen / analysis. Immunosuppressive Agents / therapeutic use. Leukemia, T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Biomarkers / analysis. Female. Humans. Male. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14617004.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / HLA-DR4 Antigen; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


85. Sasaki M, Sugimoto K, Kawahara S, Yasuda H, Suto H, Oshimi K: Rapid elimination of circulating leukemia cells with a small dose of alemtuzumab in refractory aggressive NK-cell leukemia. Eur J Haematol; 2007 Jun;78(6):545
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid elimination of circulating leukemia cells with a small dose of alemtuzumab in refractory aggressive NK-cell leukemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Lymphoid / drug therapy. Neoplastic Cells, Circulating

  • Genetic Alliance. consumer health - Aggressive NK Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419749.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


86. Rosenblum MD, LaBelle JL, Chang CC, Margolis DA, Schauer DW, Vesole DH: Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood; 2004 Mar 1;103(5):1969-71
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Lymphoid / drug therapy. Leukemia, T-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Female. Flow Cytometry. Humans. Immunophenotyping. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14976065.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


87. Haran MZ, Basous L, Berrebi A: Multiple myeloma associated with CD4+ large granular lymphocytic leukemia: a possible causal relationship. Hematol J; 2004;5(5):458-60
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple myeloma associated with CD4+ large granular lymphocytic leukemia: a possible causal relationship.


88. Hamidou MA, Sadr FB, Lamy T, Raffi F, Grolleau JY, Barrier JH: Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis. Am J Med; 2000 Jun 15;108(9):730-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / drug therapy. Leukemia, Myeloid / complications. Leukemia, Myeloid / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Aged. Female. Humans. Leukocyte Count / drug effects. Lymphocyte Count / drug effects. Middle Aged. Neutrophils / drug effects. Retrospective Studies. Treatment Outcome


89. Manabe A, Takahashi K, Shibata R, Takeuchi M, Morita M, Hosoya R: Long-term remission induced by corticosteroids, cyclophosphamide, and methotrexate in a patient with natural killer cell leukemia. Med Pediatr Oncol; 2000 Mar;34(3):224-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remission induced by corticosteroids, cyclophosphamide, and methotrexate in a patient with natural killer cell leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Killer Cells, Natural. Leukemia, Lymphoid / drug therapy

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10696134.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


90. Tse E, Chan JC, Pang A, Au WY, Leung AY, Lam CC, Kwong YL: Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia. Leukemia; 2007 Oct;21(10):2225-6
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dexamethasone / administration & dosage. Leukemia, T-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Mitoxantrone / administration & dosage. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Medical Oncology / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Leukemia. 2007 Dec;21(12):2577
  • (PMID = 17525720.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


91. Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P: Efficacy and safety of long-term (&gt;7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. Br J Haematol; 2010 Aug;150(4):480-1
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Large Granular Lymphocytic / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Drug Administration Schedule. Female. Humans. Middle Aged. Purpura, Thrombocytopenic, Idiopathic / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20456357.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


92. Miftakhova R, Sandberg T, Longno S, Bjork P, Bjornsson S, Lazarevic VL, Persson J, Bredberg A: Exploring novel therapeutic options in T-LGL, including epigenetic modulation: a case report. Leuk Res; 2010 Jul;34(7):e145-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploring novel therapeutic options in T-LGL, including epigenetic modulation: a case report.
  • [MeSH-major] DNA Methylation. Leukemia, Large Granular Lymphocytic / therapy
  • [MeSH-minor] Antigens, CD / analysis. Cell Division. Complement System Proteins / physiology. CpG Islands. Estrogen Receptor alpha / genetics. Genes, p16. HLA-A2 Antigen / analysis. Humans. Male. Middle Aged. Muromonab-CD3 / pharmacology. Promoter Regions, Genetic. Receptors, Retinoic Acid / genetics. T-Lymphocytes / chemistry. T-Lymphocytes / drug effects. T-Lymphocytes / pathology. Tumor Cells, Cultured / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20053450.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Estrogen Receptor alpha; 0 / HLA-A2 Antigen; 0 / Muromonab-CD3; 0 / Receptors, Retinoic Acid; 0 / estrogen receptor alpha, human; 0 / retinoic acid receptor alpha; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


93. Anoop P, Ravindranathan G, Osuji N, Dearden CE, Wotherspoon A, Bain BJ, Matutes E: Epstein-Barr virus negative large B-cell lymphoma during long term immunomodulatory therapy for T-cell large granular lymphocytic leukaemia. Br J Haematol; 2010 Jan;148(2):337-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus negative large B-cell lymphoma during long term immunomodulatory therapy for T-cell large granular lymphocytic leukaemia.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Leukemia, Large Granular Lymphocytic / drug therapy. Lymphoma, Non-Hodgkin / chemically induced. Methotrexate / adverse effects
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide. Disease Progression. Doxorubicin. Humans. Male. Prednisone. Treatment Outcome. Vincristine

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804452.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


94. Shen L, Au WY, Guo T, Wong KY, Wong ML, Tsuchiyama J, Yuen PW, Kwong YL, Liang RH, Srivastava G: Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood; 2007 Jul 1;110(1):469-70
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.
  • [MeSH-major] Boronic Acids / therapeutic use. Killer Cells, Natural / pathology. Leukemia, T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Apoptosis / drug effects. Bortezomib. Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Protease Inhibitors / therapeutic use. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17579189.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


95. Monjanel H, Hourioux C, Arbion F, Colombat P, Lissandre S, Regner MP, Senecal D: Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment. Leuk Res; 2010 Aug;34(8):e197-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Leukemia, Large Granular Lymphocytic / drug therapy. Salvage Therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211489.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


96. Pawarode A, Wallace PK, Ford LA, Barcos M, Baer MR: Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia. Leuk Lymphoma; 2010 Feb;51(2):338-41
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia.
  • [MeSH-major] Cyclosporine / therapeutic use. Leukemia, Large Granular Lymphocytic / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Immunosuppressive Agents / therapeutic use. Middle Aged. Neutropenia / complications. Neutropenia / drug therapy. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038217.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down






Advertisement